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ABSTRACT
THE ROLE OF ALDEHYDE DEHYDROGENASE 2 IN LIVER INJURY CAUSED
BY VINYL CHLORIDE AND HIGH-FAT DIET
Liya Chen

November 16, 2018

Background. Vinyl chloride (VC) is an abundant environmental
contaminant that causes steatohepatitis at high exposure levels. We have
shown previously that low concentrations of VC exacerbate high fat diet
(HFD)-induced liver injury in mice. The mechanisms involved in the
progression of liver injury caused by VC and HFD include oxidative stress,
inflammation, metabolic and mitochondrial dysfunction. Mitochondrial
aldehyde dehydrogenase 2 (ALDH2) serves as a key line of defense against
most reactive aldehydes, including lipid aldehydes (e.g., 4-HNE) and
chloroacetaldehyde (VC metabolite). We hypothesize that this defense may
play a key role in the interaction between HFD and VC in fatty liver disease.
Methods. Mice were exposed to VC via inhalation at concentrations below
the current OSHA limit (<1 ppm), or room air for 6 hours per day, 5 days per
week for 12 weeks. Mice were fed HFD or a low-fat control diet. Some mice
were administered ALDH2 agonist Alda-1 (i.p. 20 mg/kg, 3 times/week) for 3
v

weeks prior to sacrifice. Metabolic phenotyping, biochemical and histological
assessment of liver injury, indices for oxidative stress, inflammation and
mitochondrial function were examined. Results. ALDH2 is a direct target of
VC metabolite toxicity. Moreover, we demonstrated that ALDH2 activation by
Alda-1 pre-treatment decreased lipid accumulation, oxidative stress, and
prevented liver injury induced by acute exposure to VC metabolites. Chapter
IV describes a chronic model of low-dose VC exposure with HFD. The
interaction of VC and HFD decreased ALDH2 expression and activity in
mitochondria. Liver injury was characterized by enhanced steatosis,
inflammation and oxidative stress. This interaction correlated with
mitochondrial dysfunction and metabolic stress. Administration of ALDH2
agonist Alda-1 prevented the decrease in ALDH2 activity and conferred
profound protection against these changes caused by HFD+VC. Conclusion:
Taken together, these results support the hypothesis that ALDH2 appears to
be a direct target of VC exposure, which likely contributes to the
enhancement of liver injury under these conditions. Importantly, ALDH2 plays
a critical role in liver injury caused low-level VC exposure and HFD and may
therefore be a potential target for future therapies.
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CHAPTER I

INTRODUCTION

A. Background and the rationale for this study
1. Liver structure and function
Liver, the largest and heaviest internal organ in the human body, is
structurally and functionally complex. Unlike most organs, the liver has two
distinct blood supplies. The portal vein supplies about 75-80% of blood flow
while hepatic artery supplies 25% of the flow (1). The blood vessels divide
into small capillaries known as liver sinusoids, which then leads to lobule.
Lobules are the functional units of the liver and consist of millions of cells.
Hepatocytes are most numerous and comprise 80% of the volume of liver.
Being the workforce of liver, hepatocytes contain thousands of vital functions.
Hepatocytes contain abundant organelles including endoplasmic reticulum
(ER), lysosomes, peroxisomes and mitochondria, as well as cytoplasmic lipid
and glycogen. Due to the variety of functional components, hepatocytes play
a role in protein synthesis, lipid/carbohydrate metabolism and detoxification
(2). In addition to hepatocytes there are also several other cell types in the
liver which are vital to its overall health and function. Kupffer cells represents
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of 15% of the liver cells and derived from monocytes. They are the major
producer of cytokines contributing to inflammation. Hepatic stellate cells
(HSC) comprise 5% of liver cells and are known to be play a role in
regeneration and hepatic fibrogenesis and cirrhosis (2).
The hepatic portal blood drains from gastric, splenic and pancreatic veins
and travels to liver with various nutrients, toxins and chemicals. Liver, as the
target of toxicant exposure, initiates detoxification in response to
accumulative harmful substances. Cytochrome P450 (CYP) family is a group
of enzymes highly expressed in the liver and linked to metabolism of
endogenous and exogenous chemicals. They convert toxic chemicals into
less harmful chemicals, this can be achieved by various reactions including
oxidation, reduction and hydrolysis. However, free radicals are also generated
during this process and lead to cell damage (3). Normally, antioxidants such
as vitamin C and E protect the cell from these free radicals. When the
balance between antioxidants and toxicants is disrupted, toxic chemicals
become far more dangerous. Impaired cytochrome P450 system by toxic
compounds results in a high level of free radical generation and leads to liver
injury. Additionally, hepatocytes have the capacity to regenerate for
compensating damaged cells to preserve healthy function of the entire organ.
This protective capacity is limited, if the damage is too severe or if the injury is
chronic, hepatic cell death and irreversible injury may occur.
Multiples risk factors including host genetics (e.g. gender, ethnicity),
primary risk factors (e.g. obesity, alcohol) and comorbidities (e.g. viral
2

hepatitis, nutrition) can cause liver damage. According to different etiology or
manifestation, liver diseases are diagnosed as different types. In this study,
we mainly focused on the non-alcoholic fatty liver disease (NAFLD).
2. Non-alcoholic fatty liver disease and risk factors
Non-alcoholic fatty liver disease (NAFLD) is a clinical diagnosis that
include the presence of 5% or more hepatic steatosis in the absence of
excessive alcohol use as determined by liver imaging or biopsy in the
absence of secondary causes of hepatic fat accumulation. It ranges from
simple steatosis to non-alcoholic steatohepatitis (NASH), liver fibrosis and
cirrhosis, with its associated complications such as hepatocellular carcinoma
(HCC). The prevalence of NAFLD in the United States has risen from 18%
since 1988-1991 to 31% in 2011-2012 (4). Recent epidemic research has
shown that NAFLD is the most prominent cause of liver diseases,
representing over 75% of chronic liver disease (5). It has been reported that
up to 70% of patients with NAFLD are also affected by NASH and about 25%
of patients with NASH develop to cirrhosis (6). NASH is also a leading third
indication for liver transplantation in the United States. That contributes to a
major burden to mortality and morbidity, and it is expected to be the number
one in 2020 (7). Moreover, NAFLD not only affects liver function, but is also
related to the metabolic disorders such as diabetes (8). Therefore, it is
significant and necessary to understand the physiopathologic mechanisms of
NAFLD. NASH is a histological term that characterized by the presence of
necro-inflammatory process whereby hepatocytes become injured in a
3

background of steatosis (9). About 40% of NASH develop to progressive
fibrosis, leading to cirrhosis in 10-27% and HCC in 4-27% of those cirrhosis
(10).
As the most common type of NAFLD, NASH can be affected by many risk
factors including host genetics (e.g. gender, ethnicity), life style (e.g. smoking,
alcohol consumption) and comorbidities such as diabetes (11). Diet,
especially a diet high in fats, has been thought as an independent risk factor
of NASH. Obesity in adults is defined as body mass index (BMI) of greater or
equal to 30. The prevalence of obesity in United States is increasing in the
past few years. There are about 39.8% of adults and 18.5% of youth being
obese in 2016 (12). Based on the cohort studies, obese individuals have a
3.5-fold increased risk of liver damage and a has been reported dosedependent relationship between BMI with NAFLD progression (13). As the
obesity rate increases, the burden of obesity on liver diseases is
nonnegligible. The fat accumulated in liver varies with different degree of
obesity and even subtle changes in body weight are associated steatosis
(14). Thus, obesity can be considered as a predictor of NAFLD (15).
Environmental toxicants are another relevant cause that are thought to be
a primary risk factor of liver disease development. Long term occupational
and environmental exposures to industrial chemicals directly cause
steatohepatitis, which is termed as toxicant-associated steatohepatitis
(TASH). Increasing evidence suggests that exposure to elevated levels of
various industrial chemicals including volatile organic compounds, persistent
4

organic pollutants and toxic metals can contribute to the development of
TASH, eventually leading to liver failure (16, 17). Chlorinated hydrocarbons
are the most prevalent form of organic contaminants that cause human health
problems via groundwater or air inhalation. Vinyl chloride (VC) is a specific
type of chloride compound that is greatly concerning since it is distributed in
both liquid and gas phase. Additionally, it is known for its role as a human
carcinogen capable of damaging DNA (18). VC is therefore identified as a risk
factor that impacts human health, especially in liver (19). What is less known,
is that VC may also cause hepatic steatosis (20). The degree of liver damage
caused by VC may be correlated to dose exposure. The cases of high-dose
(> 1000 ppm) of VC induced severe liver injury has been reported (20), the
effect of low-dose of VC exposure on liver function is less studied.
3. Vinyl chloride and liver damage
Vinyl chloride (VC) monomer is a colorless gas that is widely used in
industrial chemical synthesis such as polyvinyl chloride (PVC). PVC is a
polymerized form of VC that is extensively involved in plastic manufacture.
VC doesn’t occur naturally, and it is mostly found in the industries for PVC
manufactures. Additionally, VC is the intermediate of some volatile organic
compounds such as trichloroethene (TCE), tetrachloroethene (PCE) and
dichloroethylene (DCE), which is globally applied as degreasing agent for
automotive and metal industries (21). VC is even present in cigarette
smoking, depending on the concentration of chloride in tobacco. VC is closely
related to our daily life and it serves as the commercial production that has
5

been widely consumed over 70 years in the United States (22, 23). VC
production was recently estimated at 27 million metric tons in the America
annually (22). As a representative organochlorine toxicant, VC has been
considered as a priority pollutant listed by the US Environment Protection
Agency (EPA) (24) as well as the Centers for Disease Control and
Protection’s Agency for Toxic Substances and Disease Registry (ATSDR).
Industrial discharges, landfill leaching, improper storage or disposal, as well
as atmospheric transport and deposition are important ways to enter
groundwater or air for VC. It is present in landfill leachates and in the
groundwater near military installations such as Camp Lejeune. To date, over
tens of thousands of American chemical workers have been exposed to
organochlorine pollution. Such huge amount of VC emission load causes
occupational diseases especially among the people working in chemical and
plastic industries. VC is reported to be easily absorbed in human body
through respiratory system and to affect multiple organ functions including
bronchial irritation, central nerves system impairment and liver damage (25).
The toxicity of VC was first reported in the 1970s associated with
angiosarcoma of the liver (ASL) (26, 27). In the past few decades in
Louisville, cohort studies also elucidated the relationship between VC
exposure and liver cancer (28). Attarchi et al also reported the case of altered
liver function was found in PVC workers compared with office workers in the
same industries (29). These data suggested that liver is the main target to
VC.
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Dr. Cave’s laboratory documented that workers exposed to high-level VC
had steatosis, hepatomegaly and fibrosis, in association with insulin
resistance, altered adipocytokines, and antioxidant depletion (16). It may not
be surprising that VC exposure leads to steatohepatitis because of its similar
metabolism pathway to ethanol. Concentrations of VC up to approximately
220 ppm, are metabolized through cytochrome P450 2E1 (CYP2E1) forming
the highly reactive genotoxic epoxide and chloroethylene oxide (Scheme 1.1).
Chloroethylene is either spontaneously or enzymatically converted into
chloroethanol (CE) and chloroacetaldehyde (CAA) (18). Previous work by our
lab has shown that individual treatment of CE or CAA alters cytokine
production, causes mitochondrial dysfunction, leads to disruption of hepatic
carbohydrate/lipid metabolism and exacerbates steatohepatitis (30). Those
studies showed that high-level of VC exposure is acknowledged to be an
inducer of liver injury and the effect can not be ignored. The Occupational
Safety and Health Association (OSHA) lowered the workplace air standard for
VC from 500 ppm to a safety limited dose of 1 ppm (2.5 mg/m3). The
morbidity of liver diseases is lower than before, however there are some
cases of liver injury that were still observed in the low VC exposure workers
(31, 32). This phenomenon suggests that it is possible for another risk factor
to enhance liver damage by inhaled VC.
4. Liver injury caused by fat and VC
It is demonstrated by many studies that VC toxicity is associated with the
development of liver disease. It has been well documented that workers
7

exposed to high concentrations of VC are prone to have high incidence of
liver injury, ranging from simple steatosis, steatohepatitis to fibrosis even
HCC (19). Obesity is also a risk factor for developing steatohepatitis. Fat
accumulation in the liver may mediate hepatocyte injury (33). Our recent
studies have shown that mice exposed to VC inhalation below the OSHA limit
concentration (<1 ppm), could exacerbate liver injury in combination with a
HFD. Increased inflammation, oxidative stress and mitochondrial impairment
were observed (34). Based on our previous research of the mechanisms
involved in NAFLD progression by VC and dietary fat, we aim to seek for a
novel target avenue of treating liver damage in this study.
5. Aldehyde dehydrogenases 2
Aldehyde dehydrogenases (ALDH) are a group of enzymes that are
responsible for the oxidation of aldehydes. These ALDH isoforms are
encoded by nuclear genes. Nineteen different functional genes have been
identified in the human genome and are widely expressed in multiple tissues
at the highest concentration in the liver (35). ALDH isoforms are found in
various subcellular organelles including nucleus, mitochondria, cytosol and
ER (36). ALDH2 is a tetrameric enzyme located in mitochondrial matrix
belonging to the ALDH family. It is ubiquitously expressed in all tissues but is
most abundant in the liver. ALDH2 is the most efficient enzyme in ethanol
metabolism, and it converts acetaldehyde to acetic acid. ALDH2 has the
lowest Km to this substrate. This Km is 900-fold lower than that of the other
members of ALDH family (37).
8

ALDH2 genetic polymorphism studies show that the ALDH2*2 allele is the
most relevant form of ALDH2 variant. People with ALDH2*2 allele are
susceptible to having reactions such as facial flushing and nausea after
alcohol consumption, due to a lower catalytic activity. ALDH2*2 is thought to
be the most common enzyme deficiency effect the 8% of world population
including in 35-45% Asian people (38). In the United States, ALDH2
deficiency is mostly found in the American Indian and the Asian populations
(39, 40). The role of ALDH2 in acetaldehyde detoxification and liver disease
progression has been reported in human and experimental models. High
blood acetaldehyde levels were observed in individuals with ALDH2 mutant
alleles after alcohol consumption, suggesting that the ALDH2 deficit
increased human susceptibility to alcohol-induced organ injury (41). ALDH2
knockout mice showed an increased acetaldehyde accumulation in the liver
after alcohol exposure or acetaldehyde inhalation, along with exaggerated
inflammation and fibrosis (42). In contrast, activation of ALDH2 reverses
alcohol-induced hepatic steatosis and overexpression of ALDH2 significantly
reduced acetaldehyde as well as apoptosis in mice fed with chronic alcohol
ingestion (43). These findings provide a strong rationale that ALDH2
activation plays a protective role in alcoholic fatty liver disease (AFLD).
However, the role of ALDH2 in liver injury caused by VC and dietary fat
remains elusive.
It is now understood that substrates to mitochondrial ALDH2 expand well
beyond the canonical acetaldehyde. Other aldehydes including 49

hydroxynoneal (4-HNE) and malondialdehyde (MDA) that are derived from
lipid peroxidation are also substrates of ALDH2 (44). Our lab has
demonstrated that oxidative stress as well as mitochondrial impairment
caused by 4-HNE can be reversed by activation of ALDH2 (45), indicating
that ALDH2 plays a role as an antioxidant enzyme. Indeed, ALDH2’s
protective role has been highlighted by many studies.
ALDH2 impairment has a deleterious effect on cellular function via
overburden of lipid adducts, oxidative or ER stress, increased mitophagy and
DNA damage, developing hepatic fibrosis, cirrhosis and cancer (46-48).
Epidemic research revealed that the prevalence of NAFLD tends to be higher
in the ALDH2*2 population (49). These researches suggest that ALDH2
dysfunction may be a part of the mechanisms contributing to fatty liver
disease. We have determined that mitochondrial function was impaired by VC
(34). We therefore hypothesize that ALDH2 dysfunction may play a role in
liver damage caused by VC. Our previous work showed that multiple
mechanisms were involved in the liver injury caused by VC and fat such as
oxidative stress, inflammation, ER stress (34). ALDH2 has been
demonstrated to be a protective enzyme in alcoholic liver injury via regulation
of ER stress, inflammation, oxidative stress and autophagy (50). Moreover,
ALDH2 is capable to catalyze CAA (knowns as VC metabolite) (51). We
hypothesize that ALDH2 activation will protect the liver from dietary fat and
VC exposure.
6. Statement of Goal
10

In our previous work, we showed that low-level VC exposure exacerbates
liver injury caused by dietary fat via multiple mechanisms including
inflammatory damage, oxidative stress, ER stress and mitochondrial
dysfunction. In this study, we aim to seek for a novel molecular factor as a
liver protective target. As introduced throughout this chapter, we know that
ALDH2 is an important enzyme that has been clarified to be a protective
factor in liver function against alcohol abuse in many studies. VC shares a
similar pathway for metabolism as ethanol. Therefore in this dissertation, we
hypothesize that activation of ALDH2 may affect liver injury caused by VC
and HFD, and we will investigate the role of ALDH2 in regulating liver function
recovery.

B. Specific aims in this study.
1. Aim1: Evaluate the protective role of ALDH2 againist VC
metabolite exposure in mice
This aim is mainly to investigate the role of ALDH2 in the CE or CAA
exposure (metabolites of VC). Previous work by our lab showed that CE
increased 4-HNE adducts and altered energy metabolism including disruption
of carbohydrates/lipids, CAA treatment also caused toxicity in primary
hepatocytes and HepG2 cells (30). ALDH2 is known to reduce 4-HNE
induced oxidative stress and mitochondrial dysfunction (45). We hypothesize
that ALDH2 plays a role in the protecting liver from VC metabolites. The goal
of this aim is to study whether ALDH2 prevents co-induced liver damage. The
11

potential mechanisms that could be affected by ALDH2 are investigated. We
also aim to explore the effect of CAA on ALDH2 activity.
2. Aim2: Investigate the protective role of ALDH2 against liver injury
caused by VC and HFD in mice
Recent work from our group showed that the low-dose VC exposure
enhanced HFD-induced liver injury. The role of ALDH2 in this animal model
has not been studied before. The goals of this aim are therefore to (i)
characterize whether ALDH2 function is impaired in the liver injury of our
model; (ii) to determine whether activation of ALDH2 prevent liver damage
from VC and HFD; (iii) and to explore the mechanisms involved in the effect
of ALDH2 on liver injury.

12

Scheme 1.1: VC metabolism
VC metabolism in the cell is represented. VC is metabolized through CYP2E1
and form chloroethylene oxide, which can be transformed into chloroethanol
(CE) or chloroacetaldehye (CAA). CAA can be degraded by ALDH2 into chloracetic acid
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CHAPER II

EXPERIMENTAL PROCEDURES

A. Animals and treatment
6-week old male C57BL/6J mice from Jackson Laboratory (Bar Harbor,
ME), were housed in a pathogen-free barrier facility accredited by the
Association for Assessment and Accreditation of Laboratory Animal Care, and
procedures were approved by the University of Louisville’s Institutional Animal
Care and Use Committee.
1. Acute mice model of CE exposure
During the exposure period, mice were housed in pairs in shoebox cages
in a room held at 75 ˚F. Food and tap water were allowed ad libitum. Mice
were given control diet and randomly divided into 4 groups: 1) control, 2)
Alda-1(ALDH2 activator), 3) chloroethanol (CE, 50mg/kg, i.g.) and 4) Alda1+CE. The Alda-1 group was pretreated with ALDH2 activator (20mg/kg/d i.p.)
for 3 days, on the fourth day, the mice were administered CE after 30 minAlda-1 injection. Mice were anesthetized and sacrificed the after 24h CE
treatment.
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2. Chronic mice model of VC and HFD exposure
Mice were fed low-fat control (LFD,13% calories as fat) or high-fat diet
(HFD,42% calories as fat) for 12 weeks in bedding-free cages. The mice were
exposed to VC (Kin-tek, La Marque, TX) via inhalation at the concentration
below the current limit of OSHA (~0.85±0.1 ppm) for 12 weeks (6 hours per
day, 5 days per week). Some mice were administrated room air for the same
pattern. At the end of 9th week, some mice were injected with a specific
agonist of ALDH2, Alda-1(20mg/kg i.p., 3 days/ week; EMD Chemicals,
Gibbstown, NJ), which is dissolved in the vehicle of 50% dimethylsulfoxide
and 50% polyethylene glycol. Body weight and food consumption were
monitored weekly in modeling period. Mice were sacrificed at 12 th week.
3. Oral glucose tolerance test
Blood glucose level of chronic mice model of VC and HFD was measured
at the 12th week by oral glucose tolerance test (OGTT). Transfer mice to
cages without food and bedding 6 hours prior to experiment. After fasting
period, blood was sampled from the tail cutting immediately after fasting to
determine baseline. Following oral administration of 2 mg/kg glucose (Sigma,
St Louis, MO) in 4 ml/kg of sterile saline solution, blood from tail vein was
measured at 15, 30, 60, 90 and 120 minutes for glucose level. Glucose
concentrations were tested using an Accu-Chek Aviva Plus glucometer and
test strips (Roche Diagnosis Corp., Indianapolis, IN).
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4. Animals sacrifice, samples collection and storage
At sacrifice, animals were fasted for 4 hours and anesthetized with ketamine/xylazine (100/15 mg/kg, i.p.). Blood was collected from the vena cava
just prior to sacrifice and citrated plasma was stored at -80°C for further analysis. After washing with PBS buffer, liver tissue will be collected with portions
of all tissues were snap-frozen in liquid nitrogen, embedded in frozen specimen medium (Sakura Finetek, Torrance, CA), or were fixed in 10% neutral
buffered formalin for later histological staining. Total hepatic RNA will be extracted from additional portions using RNA STAT-60 (Tel-Test, Inc., Friendswood, TX) and chloroform: phenol extraction.

B. Histology
1. General morphology
Liver tissues were fixed in formalin, paraffin embedded liver section was
cut at 5 μm and mounted on charged glass slides. Sections were
deparaffinized with Citrisolv (Fisher Scientific, Waltham, MA) and rehydrated
through addition of graded ethanol solutions. Sections were then stained with
hematoxylin and eosin (H&E). After staining, samples were dehydrated
through graded alcohol, washed in Citrisolv and then mounted with Permount
(Fisher, Waltham, MA). Pathology was scored (inflammation and necrosis) in
a blinded manner as described before, the number of inflammatory or necrotic
foci was determined ten 400x fields.
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2. Neutrophil accumulation
Neutrophil accumulation in liver tissue was measured using chloroacetate
esterase (CAE) staining. Briefly, formalin fixed, paraffin embedded liver tissue
was cut at 5 μm and mounted on charged glass slides. Sections were
deparaffinized with Citrisolv (Fisher, Waltham, MA) and rehydrated through
addition of graded solutions of ethanol. Tissue specimens were incubated in a
solution of napthol ASD chloroacetate (1 mg/ml) in N,N-dimethylformamide,
with 4% sodium nitrite and 4% new fuchsin for 25 min. The napthol AS-D
chloroacetate was enzymatically hydrolyzed by chloroacetate esterase in
neutrophils, liberating the napthol compound. Napthol combined with a freshly
formed diazonium salt, leaving bright pink color deposits at the site of
enzymatic activity. The slides were counterstained in the hematoxylin for 1530s and dipped in ammonium hydroxide solution for few seconds to stain
nucleus in blue. After staining, check liver section for counter stained color
and dehydrated them through graded ethanol, washed in Citrisolv, then
mounted with Permount (Fisher, Waltham, MA). CAE positive cells were
counted by Metamorph Imagen Analysis Software (Molecular Devices,
Sunnyvale, CA) and expressed by the ration of positive staining cells in 100
hepatocytes.
3. Lipid and glycogen accumulation
Lipid accumulation was detected via Oil Red-O (ORO) staining. This
staining was based on the great solubility of oil-soluble dyes in lipoid
substances. Oil Red-O powder was dissolved in 99% 2-proponal (Fisher
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A416-4) and make the stock solution at the concentration of 3mg/ml. Before
staining, Oil Red-O must be made freshly by mix the stock with distilled water
at the ration of 3:2. Frozen sections of liver were cut at 10 μm and stained
with Oil Red-O solution (Sigma, St. Louis, MO) for 10 minutes, washed, and
counterstained with hematoxylin for 45 seconds. Samples were then rinsed in
water and mounted with Permount (Fisher, Waltham, MA).
Hepatic glycogen reserves were visualized as a dark purple color using
Periodic Acid-Schiff (PAS) staining. Formalin fixed, paraffin embedded liver
tissue was cut at 5 μm and mounted on charged glass slides. Sections were
deparaffinized with Citrisolv (Fisher, Waltham, MA) and rehydrated through
graded ethanol. Sections were incubated in 0.5% Periodic Acid solution for 5
minutes, washed in water, and incubated with Schiff reagent for 15 minutes.
Slides were washed in lukewarm water for 5 minutes, tissue section turned
into dark pink color. Samples were then counterstained with hematoxylin for
45 seconds, washed in water, dehydrated through graded ethanol, washed in
Citrisolv, and then mounted with Permount (Fisher, Waltham, MA).
4. Immunohistochemistry
4-HNE and MDA stained liver were performed by immunohistochemistry
(IHC). Previous sectioned formalin-fixed, paraffin-embedded liver sections
were deparaffinized in Citrisolv and hydrated through descending grades of
ethanol to distilled water. Slides were incubated in target retrieving solution
overnight at 72°C. Slides were placed in room temperature and then rinsed in
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TBS. Following that, endogenous peroxidases were quenched in 3%
hydrogen peroxide. Blocking for endogenous biotin was performed using a
commercially available kit (Agilent Technologies, Santa Clara, CA). Prior to
applying primary antibody, sections were blocked in 10% goat serum in TBS0.01% Triton. Positive sections were incubated in 1:500 rabbit anti-MDA (Cell
Signaling Technologies 2956S, Danvers, MA) and negative parts were
incubated in TBS-0.01% Triton for 2 hours at room temperature. After
washing several times in TBS, tissues were incubated in a biotinylated antirabbit IgG secondary antibody from the Vectastain Elite ABC kit detection
(Vector Laboratories, Inc., Burlingame, CA) for 15 minutes at room
temperature. Slides were rinsed in TBS and then incubated in a solution
containing avidin-bound horseradish peroxidase (HRP) for 30 minutes. For 4HNE staining, using peroxidase from DAKO kit to block deparaffinize and
rehydrated tissues, slides were incubated in primary antibody of 4-HNE
(Alpha diagnostics) which was diluted in PBS-T at 1:500 for 30 minutes at
room temperature, second antibody was applied for 5 minutes. The HRP
substrate 3, 3’-diaminobenzidine (DAB) (Agilent Technologies, Santa Clara,
CA) was added to sections until positive (brown) staining was
macroscopically visible. Slides were counterstained with hematoxylin for 1
minute, washed, dehydrated through graded ethanol and then mounted with
Permount (Thermo Fisher, Waltham, MA). Each slide contained a negative
tissue section that did not receive primary antibody. Slides were visualized
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using a Nikon Eclipse E600 microscope (Nikon Corporation, Tokyo, Japan)
with Metamorph software (Molecular Devices, Sunnyvale, CA).

C. Biochemistry assay
1. AST, ALT assay
Plasma activity levels of alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) were determined spectrophotometrically using
standard kits (Thermo Fisher Scientific, Waltham, MA).
2. Lipid, glycogen extraction and quantification
A small piece of frozen liver was homogenized in tissue pulverizer, staying
as cold as possible with the liquid nitrogen. Liver powder was transferred to a
tared glass tube with chloroform and methanol addition using glass syringes.
Appropriate volume of water was added in the samples followed by a
complete vortex and sitting on ice for at least 30 minutes. Samples were
mixed with chloroform and water, then vortexed completely and centrifuged
down at a full speed. Appropriate volume of sample was taken out from the
bottom phase and transferred to a new tube. N 2 drying apparatus was applied
for drying samples. After that, dried lipids were resuspended with 200 μl 5%
lipid free BSA. For triglyceride and cholesterol measurement, standard of LDC cal solution in graded concentration were prepared with addition of
triglyceride (TG)/cholesterol reagent as described in the protocol from Infinity
kit (Thermo TR 13421). The plates were incubated in the plate reader for 5
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minutes and read at wavelength of 500 nm. Non-essential fatty acid (NEFA)
assay was measured as describe in instruction, then read absorbance at
wavelength of 520 and 680 nm.
Glycogen determination in liver was modified from Seifter et al (52). 50100 mg liver tissue was placed in 500 μl of 30% KOH and incubated in 100°C
for a complete digestion. After adding 625 μl of 95% ethanol, samples were
sitting at room temperature overnight. Samples were centrifuged at full speed
and the pellets were resuspended in water. Samples or glucose standards
were mixed with 0.2% anthrone solution by the ration of 1:2 and incubated at
100°C for 10 minutes. 150 μl of vortex samples were transferred to 96-well
plate. OD value was measured at 620 nm, glycogen was calculated by
glucose standard curve and reported at μg/g tissue.
3. ALDH2 activity assay
In the in vivo model, ALDH2 enzymatic activity was determined in
mitochondrial extracts using a commercial kit (Abcam, ab115348). The
enzyme is captured within wells of the microplates and activity is determined
by the production of NADH in the ALDH2 catalyzed reaction. The generation
of NADH is coupled to the 1:1 reduction of reporter dye to yield a colored
reaction product whose concentration can be monitored by measuring the
increase in absorbance at 450 nm. All the reagents were prepared as
described in the protocol. Mitochondrial sample pellets were mixed with
extraction buffer and centrifuged down for 20 minutes. Supernatants were
diluted and placed in the well covered with acetaldehyde. After 3 hours of
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incubation, wells were washed 3 times. The absorbance was recorded at 450
nm at 30 minutes and 120 minutes after addition of the activity solution.
Purified ALDH2 protein (10 μg) purchased from Sigma (St Louis, MO)
were added to 50mM sodium phosphate buffer (pH 7.4) containing 1mM
EDTA, 1 mM DTT and 1 mM NAD+. The reaction was initiated by the addition
of CAA (Sigma, St Louis, MO) into the 1 ml cuvette. The ADLH2 activity was
measured spectrophotometrically at 340 nm via the formation of NADH. For
Alda-1 group, ALDH2 was incubated in Alda-1 (20 μM) for 2 minutes and
measured activity immediately after CAA and NAD + addition. For CAA group,
enzyme was exposed to CAA (40 μM) for 5 minutes, added NAD + and
determined absorbance. To investigate the effect of Alda-1 intervention on
CAA exposed enzymatic function, we pre-incubated enzyme to Alda-1 for 2
minutes, then exposed it to CAA for 5 minutes and measured activity after
NAD+ addition.
4. TBARS assay
The liver MDA level was quantified by determination of thiobarbituric acid
reactive substances (TBARS) concentration using a commercial kit (R&D
system, Minneapolis, MN). Free MDA is typically low, requiring release of
MDA by acid treatment of proteins and breakdown of peroxides by heat and
acid to facilitate color development in the TBARS assay. Liver homogenate
was mixed with the same volume of TBARS acid reagent, incubated at room
temperature for 15 minutes and centrifugated. TBARS standard and sample
supernatants were placed in the 96-well plate with the addition of TBA
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reagent. The OD value of each well was pre-read using a microplate reader at
532 nm. After incubation at 45°C for 2 hours, the OD was determined again.
The pre-reading was subtracted from final the reading to correct for samples
contribution to the final absorbance at 532 nm. A standard curve was created
and MDA concentration was calculated. The MDA levels were reported at
nmol/mg protein.

D. Sample protein extraction
Liver samples were homogenized in RIPA buffer [20 mM Tris-HCl, pH 7.5,
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% (wt/vol) Triton X-100],
containing protease and phosphatase inhibitor cocktails (Sigma, St. Louis,
MO). Liver homogenates were centrifugated at full speed for 5 minutes,
supernatants were collected and stored at -80°C. Mitochondria protein was
isolated as describes by Wiekowski et al (53). Fresh liver tissues were
washed in IB-1 (225 mM mannitol, 75 mM sucrose, 0.5% BSA, 0.5 mM EGTA
and 30 mM Tris-HCl) immediately and then transferred to IB-3 (225 mM
mannitol, 75 mM sucrose and 30 mM Tris-HCl). Liver homogenates were
mixed with appropriate IB-1(4 ml/g of liver) and centrifuged at 740g for 5
minutes. Supernatants were collected and centrifuged by a higher speed at
9,000g for 10 minutes. The pellets were resuspended with IB-2 (225 mM
mannitol, 75 mM sucrose, 0.5% BSA and 30 mM Tris-HCl) following by
centrifuging at 10,000g for 10 minutes. The pellets were washed in IB-3 and
centrifugated at the same speed. After that, the pellets were dissolved in MRB
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(225 mM mannitol, 5 mM HEPES and 0.5 mM EGTA) and crude
mitochondrial proteins were stored at -20°C.

E. Immunoblots
Samples were loaded onto SDS-polyacrylamide gels (4-12%) (Invitrogen,
Thermo Fisher Scientific, Grand Island, NY), followed by electrophoresis and
Western blotting onto PVDF membranes (Hybond P, GE Healthcare BioSciences, Pittsburgh, PA). The PVDF membrane was washed in TBST buffer
and blocked by TBST containing 5% milk. The membrane was incubated in
the primary antibodies against Atg7, p62, LC-3 I/II, GAPDH (Cell Signaling
Technology; Beverly, MA), PINK1 and PARKIN (Santa Cruz Biotechnology,
Dallas, TX) of dilution in 1:1000 overnight at 4°C. Second antibodies were
used at 1:5000. Target proteins were visualized using a chemiluminescence
detection system. The expression of ALDH2 was determined using
mitochondria extraction and primary antibodies of ALDH2 diluted in 1:1000,
VDAC was performed as a loading control for mitochondria. Densitometric
analysis was performed using UN-SCAN-IT gel (Silk Scientific Inc., Orem,
UT) software.

F. RNA Isolation and Real-Time qPCR
RNA was extracted immediately following sacrifice from fresh liver
samples using RNA Stat60 (Tel-Test, Ambion, Austin, TX) and chloroform.
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Sample mixtures were centrifugated at 12,000g for 15 minutes at 4°C. The
aqueous phase was transferred into a new tube, mixed with isopropanol and
subsequently centrifugated completely. The pellets were washed in 75%
ethanol. After removing supernatant by centrifuging, the pellets were
resuspended with RNAse free water in 65-70°C for 5 minutes. RNA
concentrations were determined spectrophotometrically and 1μg of total RNA
was reverse transcribed using a kit (Quanta Biosciences, Gaithersburg MD).
Real-time qPCR was performed using a Step One real time PCR system
(Thermo Fisher Scientific, Grand Island, NY). Primers and probes were
ordered as commercially available kits (Thermo Fisher Scientific, Grand
Island, NY). The comparative CT method was used to determine fold
differences between the target genes and an endogenous reference (18S).

G. Hepatocytes and cellular function analysis
1. Primary hepatocytes isolation and culture
Mice were anesthetized with ketamine/xylazine (100/15 mg/kg, i.p.).
Thread was set around inferior vena cava (IVC). Catheter was inserted into
the vein in an appropriate position by visualizing a backflow of blood. EGTA
solution was connected to catheter to perfuse liver (5 ml/min) for 6 minutes,
then switch to collagenase buffer for 10 minutes. Liver was taken out and
minced well in Waymouth media. The cells were filtered and centrifuge at a
low speed for several times. After washing the cell pellet with HBSS buffer,
the hepatocytes were seeded in the collagen covered plate at density of
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10,000 cells per well. Cells were washed with HBSS after 90 minutes of
incubation at 37°C.
2. Hepatocytes cytotoxicity measurement
Primary hepatocytes isolated from 12-week HFD fed mice exposing to VC
were then exposed to CAA (Sigma) at the different concentration for 1 hour in
the incubator. Media containing Hoechst 33342 (1.5 μM, nuclear
fluorescence), TMRM (20 μM, mitochondrial membrane potential indicator),
TOTO-3 (1μM, index of cell membrane permeability), fluo-4 AM (1μM,
intracellular ionized Ca) and MitoSox (5 μM, mitochondrial superoxide
indicator) dye was add to the wells after CAA treatment. Following 45 minutes
incubation with mixed dye, the plate was placed into the Cellomics Assay San
VTI HCS reader and analyzes as previously described by O’Brien et al (54).
Ten fields per well at the 20× objective was used to collect images for valid
cell count (defined by Hoechst 33342 staining). The average of individual
values for all fluorophores for each valid object was analyzed.
3. Hepatocytes oxygen consumption rates measurement
Primary hepatocytes were placed at 10,000 cells per well on collagencoated XF96 culture microplate (Seahorse Biosciences, Billerica,
Massachusetts) and incubated at 37 °C to allow cell attachment. Cells were
pre-exposed to Alda-1 at 20 μM for 30min and changed to XF medium
(Seahorse Biosciences) containing the same concentration of Alda-1. For
mitochondrial respiration measurement, hepatocytes were injected with CAA
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(40 μM), oligomycin (1 μg/ml), FCCP (4 μM), antimycin A (10 μM) and
rotenone (10 μM). The injected compounds were diluted in XF medium.
Oxygen consumption rates (OCRs) were measured using an XF96
Extracellular Flux Analyzer (Seahorse Biosciences, Billerica, Massachusetts).
H. Statistic analysis
Results were reported as means ± SEM (N=4-7) and analyzed using
Sigma Plot 11.0 (Systat Software, Inc; San Joes, CA). ANOVA with
Bonferroni’s post host test (for parametric data) or Mann-Whitney Rank sum
test were used for determination of statistical significance among treatment
groups, as appropriate. A p value < 0.05 was selected before the study as
the level of significance.
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CHAPTER III
ALDH2 PROTECTS LIVER FROM VC METABOLITES

A. Introduction
The liver is the largest organ in the body and serves as the most complex
organ in terms of metabolism. It plays a critical role in the metabolism of
amino acids, biochemical oxidation and detoxification of drugs or
environmental toxicants. Due to the role of liver functioning as the first line of
defense, the liver is also the most common organ to be damaged by toxicants
or chemicals. Industrial chemicals induced hepatocyte toxicity is depended on
dose exposure (55). VC is an environmental toxicant ranked #4 on the
ATSDR substances priority list that known to induce hepatoxicity (56). Highlevels of VC exposure have been demonstrated to be associated with
occupational liver diseases such as steatohepatitis (TASH), liver cancer (30).
Thus, we aim to find a potential target factor for protecting the liver from VC
exposure. VC has a similar metabolic pathway to ethanol. VC is metabolized
to CE and subsequently forms into CAA depend on aldehyde dehydrogenase
pathways, therefore CE or CAA may be an important mediator in VC-induced
liver injury.
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Previous work by our lab has shown that CE slightly increases liver
damage through elevating 4-HNE adducts, which is an index of oxidative
stress, destroying energy metabolism including increased lipid droplets and
depleted glycogen reserves in the liver (30). CAA damaged mitochondrial
function and directly impaired cell viability in hepatocytes (30). These data
demonstrated that VC metabolites are detrimental to the liver and could be
the mediator in liver damage caused by VC inhalation. Mitochondrial
dysfunction is known to be a part of mechanisms attributing to VC metabolites
induced hepatocytes damage (30, 34). Protecting mitochondria may reduce
CE or CAA caused cytotoxicity.
It is now accepted that substrates for ALDH2 go well beyond the canonical
acetaldehyde, namely lipid aldehydes (e.g. malondialdehyde) are also
reduced by ALDH2 (see also Chapter I). Indeed, we previously have found
activation of ALDH2 protected mitochondrial function from 4-HNE cytotoxicity
related mitochondrial membrane polarization and reduced oxidative stress in
liver (45). The mitochondrion is the main organelle for cellular energy supply,
which is especially important for carbohydrate and lipid metabolism. Thus,
ALDH2 is proposed to protect mitochondria and to therefore maintain energy
metabolism homeostasis. Whether ALDH2 plays a role in protecting liver of
mice exposed to VC inhalation remains unclear. Therefore in this section, we
aim to study the role of ALDH2 in the presence of VC metabolites instead of
chronic VC inhalation.
Since CAA is also a substrate of ALDH2 (51), it is reasonable to speculate
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that cell damage caused by CAA can be attenuated by ALDH2 and that effect
may be via protecting mitochondrial function, normalizing energy homeostasis
and oxidative balance. In this Chapter, we will investigate the impact of
ALDH2 on liver phenotype and explore the mechanisms involved in.

B. Results
1. ALDH2 regulates energy metabolism in liver of acute CE exposed
mice
Lipid accumulation and glycogen deposition are the important aspects that
reflect fat and glucose metabolism in liver. Therefore, we performed analysis
of lipids and glycogen by staining the quantitative level by hepatic extraction
using commercial kits. ORO staining of neutral lipids showed that CE
treatment caused an increase in lipid droplet accumulation. Pre-treatment of
Alda-1 decreased ORO positive staining in the CE group (Figure 3.2A). This
was also reflected in triglyceride (TG) levels in liver and plasma. CE or Alda-1
alone did not change NEFA and cholesterol levels in either liver or plasma
(Figure 3.2B). Hepatic glycogen storage was visualized by PAS staining. CE
caused an obvious depletion of glycogen deposition while Alda-1 did not blunt
this effect (Figure 3.2A). Quantitation of PAS staining in liver also showed that
CE significantly decreased glycogen stores. This was not prevented by Alda-1
pre-exposure (Figure 3.2B). Hepatic steatosis and glycogen depletion was
mediated by alteration in expression of metabolic associated gene. To
explore the regulation of ALDH2 in lipids and carbohydrates homeostasis, we
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analyzed the expression of genes involved in the synthesis and catabolism of
fat or glucose by RT-qPCR (Scheme 3.2).
Carnitine palmitoyltransferase 1a (CPT1) is the rate-limiting enzyme in
fatty acid β-oxidation in the mitochondria. ATP citrate lyase (ACLY) is
an enzyme representing an important step in fatty acid biosynthesis. It
converts citrate to acetyl CoA, which is an intermediate link the metabolism of
carbohydrates and production of fatty acids. Fatty acid synthase (FAS) is a
multi-enzyme protein that catalyzes fatty acid synthesis. ALDH2 activation by
Alda-1 significantly increased Cpt1 expression suggesting that ALDH2
activation increased fatty acid β-oxidation in the mitochondria. There was no
significant difference of Fas and Acly mRNA expression in each group (Figure
3.3).
Glucose transporter (GLUT4) permits glucose to enter the cell and
increases glucose absorption, glucokinase (GCK) is a rate-limiting enzyme in
glycolysis that facilitates phosphorylation of glucose to glucose-6-phosphate,
it plays an important role in the regulation of carbohydrate metabolism.
Glycogen synthase kinase 3b (GSK3b) increases the phosphorylation of the
gluconeogenic enzymes, suppressing glycogen synthesis.
Phosphoenolpyruvate carboxykinase (PCK) is a rate-limiting enzyme that
catalyzes an irreversible step of gluconeogenesis and thought to be essential
in glucose homeostasis. SIRT1 is a factor involving hepatic glucose and lipid
hemostasis. However, by PCR data we found that none of these markers
showed significantly different mRNA expression in each group (Figure 3.3).
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2. ALDH2 activation inhibited CE-induced oxidative stress in liver
4-HNE is a byproduct of lipid peroxidation and thought to be an indicator
of oxidative stress. Previous work by our lab showed that CE increased
oxidative stress in liver (30). For investigating whether ALDH2 functioning in
protecting liver from CE, 4-HNE protein adduct accumulation was measured
by staining and expressed by quantitation of positive staining. CE increased
in 4-HNE positive staining comparing to control mice, pre-injection by Alda-1
decreased 4-HNE adducts level in the CE mice (Figure 3.4).
3. The effect of ALDH2 on proinflammatory cytokine gene expression in CE mice
We also wanted to know how ALDH2 affected the inflammatory response
in liver. Pai-1 is a plasminogen activator inhibitor that inhibits fibrinolysis. It is
also known as a proinflammatory cytokine. Tumor necrosis factor-α (TNF-α) is
a pleiotropic cytokine produced by a variety of immune cells including
macrophages/monocytes. TNF-α can trigger multiple signaling pathways
involved in inflammation. Moreover, TNF-α has been shown to be an
upstream regulator of PAI-1 (57). However, neither CE nor Alda-1 significantly
changed mRNA expression of Pai-1 and Tnf-α (Figure 3.5).
4. Pre-incubation of Alda-1 prevented reduction in ALDH2 activity by
CAA
ALDH2 is known to protect liver injury by decreasing 4-HNE caused
oxidative stress or reducing lipid accumulation (45). There are multiple signal
32

pathways involved in the animal model so that might be complex to figure out
a predominant mechanism contributing to liver protection. ALDH2 utilizes
aldehydes as substrate and NAD+ as cofactor to form into their corresponding
acid. It is known that 4-HNE is one of the substrates to ALDH2 (58), activation
of ALDH2 is demonstrated to play a critical role in aldehyde clearance thereby
leading to cell protection (59). We want to know how ALDH2 performs in the
exposure of CAA and explore a direct reaction between enzyme and toxic
CAA. Purified ALDH2 were measured for enzyme characterization. We
proved that CAA acted as the substrate for ALDH2, moreover, prolonged
single CAA treatment blocked the utilization of NAD+ to form NADH and
showed a significant inhibited ALDH2 activity. Alda-1 pre-treatment elevated
enzymatic activity in both control and CAA group (Figure 3.6).
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Scheme 3.1: animal treatment by CE and Alda-1
Mice received Alda-1(20mg/kg) injection for 4 days and were gavaged with CE
(50mg/kg) 24 hours prior to sacrifice. For mice of Alda-1+CE group, CE was
given after 30 minutes Alda-1 treatment.
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Figure 3.2. The effect of ALDH2 on hepatic lipids and glycogen level in CE
treated mice.
A. Representative photomicrographs of ORO (neutral lipid, red) and PAS
(glycogen, dark purple) staining are shown at 200x magnification. B. Hepatic
and plasmatic TG, cholesterol and FFA level were measured as described in
Chapter II, quantitative positive staining of glycogen storage in liver was
expressed by Image Metamorph analysis software. Results are reported as
means ± standard error mean (SEM; n=4-6). a, p<0.05 compared to control
group, b, p<0.05 compared to absence of Alda-1.
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Scheme 3.2: energy metabolism related gene regulation
Changes in glucose and lipid metabolism are represented. Carbohydrates metabolism related genes includes Glut4, Gck, Pck, Gsk3b. Lipid metabolism related gene includes Cpt1, Acly, Fas. Sirt1 serves as the regulator in both glucose and lipid homeostasis.
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Figure 3.3. The effect of ALDH2 on energy metabolism related mRNA expression in CE mice
Lipid metabolism mRNA (Cpt1, Fas, Acly) and carbohydrate metabolism mRNA
(Gsk3b, Gck, Pck, Glut4, Sirt1) expression in liver homogenate were measured
by RT-qPCR in mice treated with CE or Alda-1. Results are reported as means
± standard error mean (SEM; n= 4-6),

a,

p < 0.05 compared to control mice,

p < 0.05 compared to the absence of Alda-1.
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b,
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Figure 3.4. The effect of ALDH2 on liver oxidative stress caused by CE
A. Representative photomicrograph of 4-HNE staining (index of oxidative
stress, brown) in liver are shown at 200x magnification. B. Quantitative positive
staining of 4-HNE adducts in liver was expressed by Image Metamorph
analysis software. Results are reported as means ± standard error mean (SEM;
n=4-6). a, p<0.05 compared to control group, b, p<0.05 compared to absence
of Alda-1.
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Figure 3.5. The effect of ALDH2 in proinflammatory cytokines mRNA expression in the CE group
Hepatic mRNA expression in liver homogenate of proinflammatory cytokines
(Tnf-α, Pai-1) were measured by RT-qPCR in mice of all groups. Results are
reported as means ± standard error mean (SEM; n= 4-6), a, p < 0.05 compared
to control mice,

b,

p < 0.05 compared to the absence of Alda-1.
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Figure 3.6. Purified ALDH2 characterization
ALDH2 enzymatic activity was measured in purified protein after treating with
CAA or Alda-1 as described in Chapter II. The activity was determined at 1 min
time point after substrate addition. Results are reported as means ± standard
error mean (SEM; n= 4-6),

a,

p < 0.05 compared to control group,

compared to the absence of Alda-1.
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b,

p < 0.05

C. Discussion
As mentioned in the Introduction, NAFLD is composed of steatosis and
steatohepatitis that potentially develops to hepatic fibrosis and cirrhosis.
Steatosis or steatohepatitis are considered a hallmark for diagnosis of earlystage liver damage. Environmental toxicants such as VC cause hepatic
steatohepatitis. Most clinical cases were found in workers with chronic
occupational exposure to VC at high concentrations (20). CE and CAA,
metabolites of VC, are important mediators in VC induced liver damage.
Here, we exposed mice to acute CE at a concentration which equates to ~100
ppm of VC bolus rodents. The concentration of CE was determined by others
to not directly cause liver damage (60) and was validated in our previous work
(30). Activation of ALDH2 has been shown to be a protective, especially in
alcoholic liver disease (43). The role of ALDH2 in VC exposed liver function
has not been studied. Here, our first aim was to investigate the effect of
ALDH2 activation in an animal model of short-term treatment of CE. We
determined by ORO staining that CE increased lipid accumulation in liver.
The main form of lipid storage in hepatocytes are TG. Other lipids that can
accumulate are FFA or free cholesterol (61). Elevated TG levels in both liver
tissue and plasma were observed in CE-treated mice. Alda-1 pre-treatment
attenuated lipid droplet formation in the liver, paralleled with an decrease in
TG levels (Figure 3.2). Hepatic TG accumulation is mainly synthesized from
FFA. We speculated that the effect of CE or Alda-1 on TG showed a
consistent trend with FFA level. However, neither CE nor ALDH2 changed
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FFA level (Figure 3.2). FFA content is depended on the lipolysis, lipid
synthesis and the destination such as FFA oxidation in mitochondria (7). We
measured some key gene in catalyzing FFA synthesis (Acly, Fasn) by PCR,
however there was no significant difference found in each group. CE didn’t
alter Cpt1 mRNA expression while Alda-1 caused significantly upregulated
expression levels (Figure 3.3). This suggested that CE did not affect FFA
lipogenesis or oxidation. The effect of ALDH2 in lipids metabolism might be
attributed to the increased FFA oxidation in mitochondria. Overall, these data
indicate that ALDH2 activation is sufficient to inhibit CE mediated steatosis.
Additionally, previous data in our lab showed that CE decreased hepatic
glycogen storage due to an increased demand of glucose compensation for
ATP depletion which is derived from CE caused mitochondrial impairment
(30, 34). The protective role of ALDH2 in mitochondria has been
demonstrated previously (45). Here we measured the effect of ALDH2 on
glycogen deposition in liver. Glycogen can be impacted by some key
metabolic process such as glycolysis, glycogenolysis, glycogenesis and
gluconeogenesis. In this study, CE did not affect mRNA expression of genes
(Glut4, Pck, Sirt1, Gsk3b, Gck) involved in glucose homeostasis but showed
a decrease in glycogen levels in the liver (Figure 3.3). However, this may be
due to temporal differences in gene expression and appearance of an altered
phenotype. The effect of ALDH2 on glycogen levels was parallel with the
performance of gene expression (Figure 3.2). However, activation of ALDH2
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does not seem to play a significant role in regulating glucose metabolism in
the acute CE exposure model.
Excessive fat production has been shown to promote low grade
inflammation by increasing expression of proinflammatory cytokines resulting
in further damage and/or fibrogenesis (7). TNF-α is a key factor involved in
the M1 response that mediates steatohepatitis (62). PAI-1 contributes to liver
lipid transport in the early stages of liver injury leading to steatosis, in the later
stages, PAI-1 acts as a key regulator in inflammation or fibrosis (63). By our
study, the mRNA level of Tnf-α and Pai-1 weren’t altered by CE or Alda-1
significantly (Figure 3.5). This result indicates that these factors are not major
players in the mechanism(s) of action in this model.
It is accepted that increased lipid accumulation and liver damage are
linked with oxidative stress (64). increased lipid deposition is the source of
endogenous aldehydes such as 4-HNE. ALDH2 is known for its role in
aldehydes degradation and antioxidant. Indeed, we demonstrated ALDH2
activation reversed lipid accumulation and suppressed 4-HNE level (Figure
3.4). These results indicate that activation of ALDH2 protects the liver from
CE-induced oxidative stress. The VC metabolite, CAA is a reactive aldehyde
similar to 4-HNE that has been demonstrated to cause hepatocellular damage
by our previous work (30). CAA has been demonstrated to be not only
substrate to ALDH2, but also a direct inhibitor of ALDH2 enzymatic activity
(Figure 3.6). It has been known that aldehydes inactivate ALDH2 by
interfering with the correct binding of the substrate to the active site or
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disrupting protein-substrate interaction (58). We hypothesize that CAA reacts
with ALDH2 at the active site and affects the binding of NAD+ and therefore
blocks the enzymatic activity. We showed that pre-incubation of ALDH2 to
Alda-1 affected the decrease in enzymatic activity caused by CAA. As a
selective ALDH2 agonist, Alda-1 binds to the entrance of the active site but
does not interfere with catalytic residue; it permits substrate binding and
facilitates catalytic product release, protecting enzymatic activity (38, 65). We
proposed that pre-activation of ALDH2 prevented enzymatic activity from CAA
inhibition and blunted decreased aldehydes clearance, this effect decreased
the production of CAA and other endogenous aldehydes (e.g. 4-HNE), and
therefore attenuated liver damage.

D. Conclusion
In this aim, we demonstrated that Alda-1 pre-treatment plays a role in
protecting the liver from acute CE exposure. Alda-1 improved metabolism
dyshomeostasis, especially on the lipids level and it decreased 4-HNEassociated oxidative stress. We suggested that this effect was initiated by
activation of ALDH2-mediated clearance of toxic aldehydes. CAA inhibited
ALDH2 activity and enhanced production of aldehydes, leading to liver injury.
Alda-1 activates ALDH2 and prevents inhibition of enzymatic activity by CAA.
As major metabolites of VC, CE and CAA are mediators of VC-induced liver
injury. We therefore hypothesize that ALDH2 is impaired by inhalation of VC
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proper and that ALDH2 activation may ameliorate liver injury caused by
chronic VC exposure.
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CHAPTER IV
ALDH2 FUNCTIONS IN PROTECTING LIVER AGAINST CHRONIC VC EXPOSURE CONCOMITANT WITH HIGH-FAT DIET

A. Introduction
VC was first used commercially in the 1920s, the techniques was not
devised to polymerize VC into a stable PVC until 1930s. Over that period,
workers were required to clean up the reaction tank because a film of PVC
forms inside wall of reactor after the polymerization finished, so that the
workers were exposed to high concentration of VC up to 1,000 ppm or higher
peaks of exposure (21). This occupational exposure of VC caused multiple
complications such as liver cancer. The cases of hepatic angiosarcoma (ASL)
were diagnosed in 1974 among VC workers in Louisville, Kentucky (66).
Additionally, the mortality risks of other liver cancers (e.g. HCC) were
associated with VC exposure (19). Based on those epidemiological
investigations, VC exposure is regarded as a carcinogen of liver as evaluated
by IARC. ASL and HCC, as the typical VC-induced liver cancers, were
normally observed in workers exposed to high concentrations of VC. Since
1975, OSHA has set stricter limitations for VC exposure (1 ppm, 8hrs/day),
which efficiently decreases morbidity of occupational acute exposure of VC
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related liver diseases. However, to this day it is unclear if low concentrations,
that are currently considered safe, may enhance or alter liver injury caused by
other risk factors. The risk for low-dose chronic exposure of VC therefore
remains a concern for workers and residential populations surrounding to
industrial or VC-contaminated sites.
As a terminal state of liver disease, liver cancer can be mediated by highlevel VC exposure. We have shown that chronic low-dose VC exposure
mediates low to moderate degrees of liver damage and we hypothesize that
these concentrations may also potentially contribute to more severe and
irreversible stages of liver injury. It is proposed that additional other risk
factors synergistically lead to progression of liver damage, ultimately leading
to fibrosis and liver cancer (67). Obesity is the most prevalent underlying
disorder that impacts over 50% of the US population (see also Chapter I).
NAFLD is the major hepatic manifestation associated with obesity. Previously,
we have demonstrated that VC dysregulates metabolic homeostasis and
enhances liver injury caused by high-fat diet (34). ALDH2 is accepted to be a
protective enzyme for its pivotal role in metabolism regulation as well as
clearance of aldehydes, which results in reduced oxidative stress. Indeed, we
have data supporting a similar mechanism in our animal model of acute CE
exposure (see Chapter III).
In this section, we focused on the effect of ALDH2 on liver function in the
interaction of chronic low-dose of VC exposure and consumption of a high-fat
diet. We have shown previously that the mechanisms involved in the chronic
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low-level VC exposure induced liver injury in HFD fed mice is similar to that of
single acute CE exposure (34). Here, we proposed that ALDH2 activation will
decrease liver injury caused by VC and HFD. Although we will determine the
role of ALDH2 in the interaction of VC exposure and HFD in vivo, it is
extremely difficult to obtain complete toxicological data due to the various cell
types and multiple signal pathways that are involved. For further
investigations of the underlying mechanism(s), we will utilize cell culture
models and document pathological changes on organelle and molecular level.
Mitochondria are key to maintaining cellular energy homeostasis. Previous
work by our lab showed CAA causes cellular damage to HepG2 and primary
hepatocytes via mitochondrial dysfunction, involving mitochondrial respiration
impairment as well as decreased mitochondrial membrane potential (30).
Furthermore, cellular toxicity induced by 4-HNE can be reversed by ALDH2catalyzed aldehyde degradation (45), which is also supported by the data
shown in Chapter III. Thus, we hypothesize that activation of ALDH2 protects
hepatocytes from VC and HFD, and we aim to investigate the involved
mechanisms as well.

B. Results
1. ALDH2 dysfunction is involved in the interaction of VC and HFD
in liver
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ALDH2 is a critical enzyme for aldehyde metabolism as well as a
protective factor in liver injury. However, the role of ALDH2 function in
exposure to VC has not been elucidated yet. For investigating ALDH2
function in this model, hepatic mitochondria were isolated from mice exposed
to VC and HFD for12 weeks. Western blot and enzymatic activity assays
were performed for determination of protein expression levels and of
aldehyde clearance rate, respectively. Figure 4.2 shows the effect of VC and
HFD on ALDH2 protein expression and activity in vivo. VDAC was used as a
loading control for mitochondrial protein. ALDH2 protein levels were
quantitated by densitometric analysis. Western blot results showed a
significant difference in ALDH2 levels between control and mice exposed to
VC inhalation (Figure 4.2A). Quantified protein level was expressed as the
ratio of intensity of ALDH2 to VDAC. HFD significantly increased ALDH2
protein expression compared to LFD feeding mice, VC exposure significantly
decreased ALDH2 levels in both LFD and HFD groups. Interestingly, the
ALDH2 enzymatic activity of HFD showed a different trend from the Western
blot results. HFD feeding significantly decreased ALDH2 activity in the liver
compared to LFD control, while the addition of VC enhanced this effect only in
the presence of HFD (Figure 4.2B). This result supports the hypothesis that
VC-enhanced liver injury in the HFD group might be via, at least in part,
regulating ALDH2 function.
2. ALDH2 affected metabolic phenotype of mice in the interaction of
VC and HFD
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For evaluating the metabolic phenotype of mice, body weights were
measured once per week and food consumption was monitored twice per
week. Blood glucose levels were determined at the 12-week time point.
Figure 4.3 A shows that there was no difference in body weights between the
LFD and LFD+VC groups. Body weights were significantly increased with
HFD. VC did not further increase body weights. Mice injected with Alda-1
were significantly lighter in body weight compared to non-Alda-1 treated mice.
Figure 4.3B shows the amount of food consumed by each dietary group
throughout 10 weeks. All these groups consumed similar amounts of food
and no significant difference was observed (Figure 4.3B). Figure 4.3C shows
blood glucose levels at different time points after administration of glucose.
None of the groups showed significantly different baseline glucose levels. At
15, 30, 60, 90, 120 min, blood glucose levels of HFD fed mice were
significantly higher than that of LFD control. However, glucose level of neither
LFD nor HFD mice was changed by VC addition. Alda-1 significantly
decreased blood glucose levels compared to mice without Alda-1. The area
under the curve (AUC) of OGTT, shown in Figure 4.3C, was not altered by
either HFD or VC, while activation of ALDH2 with Alda-1 significantly
decreased AUC, suggesting an increase in glucose tolerance.
3. Activation of ALDH2 attenuated liver injury caused by HFD and
VC
Figure 4.4A shows representative photomicrographs depicting general
hepatic morphology (H&E). No obvious pathological changes were observed
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in liver tissue of LFD groups and VC did not enhance this effect. HFD fed
mice showed obvious steatosis while VC did not visibly change this effect.
Alda-1 intervention, however decreased hepatic steatosis. Liver pathology
scores for inflammation and necrosis are shown in Figure 4.4C. While HFD
significantly increased liver pathology scores compared to LFD, VC did not
change this effect. ALDH2 activation by Alda-1 decreased hepatic
inflammation significantly in both HFD groups. The enzymatic activity of
transaminases AST and ALT were determined in plasma as a marker of liver
injury (Figure 4.4B). LFD control had normal plasma transaminase activity
and VC did not significantly alter that. HFD alone significantly increased both
ALT and AST activity. in the HFD group VC inhalation significantly enhanced
this effect. Importantly, Alda-1 significantly decreased transaminase activity,
both in the HFD and in the HFD+VC group.
4. ALDH2 decreased neutrophil infiltration and oxidative stress in
livers of VC and HFD
Figure 4.5A shows representative photomicrographs depicting neutrophil
accumulation (CAE) and oxidative stress (MDA) in livers of mice exposed to
VC for 12-week. HFD alone slightly promoted inflammatory cell recruitments
and the addition of VC enhanced this effect. Alda-1 significantly reduced
these markers. Neutrophil infiltration was quantitated and expressed as the
ratio of CAE positive cells to hepatocytes (Figure 4.5B). HFD significantly
increased the amount of CAE positive cells comparing to LFD group, which
was furtherly increased by VC. Alda-1 significantly alleviated inflammatory cell
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accumulation in livers of mice exposed to HFD and VC. MDA is the main
byproduct of lipid peroxidation and is typically used for evaluating cellular
oxidative stress. LFD and LFD+VC showed mild positive staining of MDA in
liver, HFD alone caused a stronger staining compared to the LFD controls
(Figure 4.6A), but VC did not enhance this effect. However, Alda-1
suppressed lipid peroxidation in mice exposed to HFD+VC. These data were
also reflected in a quantitative TBARS (Figure 4.6B).
CYP2E1, is known as the major enzyme in drug metabolism as well as in
metabolism of xenobiotics (68). Also, CYP2E1 mediated ROS production is a
part of cause of alcohol induced liver injury (69). In our study, whether ALDH2
affects CYP2E1 expression in the interaction of HFD and VC remains
unknown. As Western blots show (Figure 4.7), HFD and HFD+VC significantly
increased CYP2E1 protein expression comparing to the respective control
groups, and these effects were reversed by Alda-1.
5. ALDH2 reversed metabolic disorders in the interaction of HFD
and VC.
Lipid accumulation and glycogen storage are associated with energy
metabolism in liver, disruption of carbohydrate/lipid homeostasis can
potentially impact hepatic regeneration and induce hepatotoxicity (70). Liver
sections were stained for ORO and PAS to evaluate hepatic metabolism.
Figure 4.8A shows representative photomicrographs depicting lipid and
glycogen deposition and quantitative analysis of hepatic glycogen and lipid
levels. LFD and LFD+VC showed normal fat accumulation in ORO stained
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livers. As expected, more lipid droplets accumulated in HFD fed mice, and
this was enhanced by VC. Quantitative lipids were measured by TG and
NEFA analysis were expressed as the ratio of lipid amount to liver weight
(Figure 4.8B). HFD significantly increased TG, NEFA and cholesterol
production in liver comparing to LFD group, however VC enhanced this effect
only on TG levels. Alda-1 intervention reduced both hepatic TG and NEFA
levels significantly. However, cholesterol levels were further increased by
ALDH2 activation. Hepatic glycogen content as visualized by PAS staining,
was normal in the LFD and the LFD+VC group. HFD and HFD+VC decreased
hepatic glycogen stores, which was restored by Alda-1 administration (Figure
4.9A). Quantitative analysis of hepatic glycogen level shows a similar trend
(Figure 4.9B), albeit not significant.
6. ALDH2 decreased liver damage via participating in autophagy
regulation
Autophagy is considered an adaptive process that degrades unwanted,
excess and/or damaged cytosolic components in response to multiple cellular
stressors including oxidative stress and pharmacological insults. Ubiquitinactivating enzyme Atg7 is required for conversion of the soluble form of LC3I
to autophagic vesicle associated form of LC3II which is associated with the
autophagosome membrane and also serves as an index of autophagy.
Sequestosome 1 (p62) interacts with LC3II and is subsequently degraded.
Impaired autophagy causes p62 accumulation in the cell; thus, decreased
p62 also reflects autophagic activity (71, 72). Our previous data showed that
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mitochondrial function was impaired by VC (34). The cell removes damaged
mitochondria to control mitochondrial quality, this process is mediated by
mitophagy, a subtype of autophagy. The autophagic recognition of damaged
mitochondria is mediated by the PINK/PARKIN signalling pathway (73). As
the Western blot results show (Figure 4.10), HFD and HFD+VC increased
Atg7 expression significantly compared to their respective control mice. Alda1 didn’t affect Atg7 level but caused a significant decrease in p62 protein
expression. VC increased the ratio of LC3II to LC3I in LFD and HFD mice,
while Alda-1 had no effect on LC3II expression. ALDH2 activation significantly
suppressed PINK1/PARKIN level in the HFD and HFD+VC groups.
7. The effect of ALDH2 in cytotoxicity of primary hepatocytes
As the data above have shown (Figure 4.1) activation of ALDH2 protects
the liver from damage caused by the combination of VC inhalation and HFD.
There are multiple signalling pathways and cell types involved in animal
models, making an in depth analysis complicated. Therefore, in addition we
utilized cells for investigating the effect of ALDH2 on cellular function directly.
Primary hepatocytes isolated from mice fed a HFD for 12-weeks in
combination with VC inhalation ± Alda-1, were used for measurement of
cytotoxicity parameters as described in previous section. Furthermore, we
investigated whether the hepatocytes were more susceptible to damage by
the ex vivo addition of CAA.
TMRM dye acts as an indicator of mitochondrial membrane potential.
which is an essential component in the process of energy generation
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reflecting oxidative phosphorylation. The cell maintains stable levels of
mitochondrial membrane potential for normal cellular function, therefore
changes to this factor may induce loss of cell viability and various pathologies
(74). TOTO-3 is a nucleic acid dye that can not penetrate intact cells but
stains permeabilized, damaged cells (75). Fluo-4 AM is a dye that has been
widely used as an indicator of intracellular free calcium concentration. Large
increases of intracellular calcium are thought to trigger apoptosis (76).
MitoSox is a novel fluoroprobe for selective detection of superoxide
production in mitochondria of living cell, indicating oxidative stress (77). Via
HCS analysis of hepatocytes, there was no significant difference of these
indices of cytotoxicity (TMRM, TOTO-3, Fluo-4, mitoSox) among the groups.
Ex vivo exposure to CAA significantly decreased TMRM fluorescent intensity
and increased mitoSox levels. This effect was not reversible by Alda-1
(Figure 4.11).
8. ALDH2 protected mitochondrial function from VC metabolites in
primary hepatocytes
Mitochondrial function is indicative of altered mitochondrial respiration.
Previous work by our lab demonstrated that VC metabolites (CAA) directly
impaired mitochondrial membrane potential, decreased oxygen consumption
rate (OCR) which represented mitochondrial reserve bioenergetic capacity
(30). Our recent work also showed that ALDH2 reversed decreased
mitochondrial membrane potential caused by 4-HNE exposure (45). We
hypothesized that CAA causes mitochondrial dysfunction that can be rescued
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by activation of ALDH2. To explore this hypothesis and the effect of ALDH2
activation on the impairment of mitochondrial respiration, Seahorse
bioenergetic analysis for electron transport chain function was performed on
murine primary hepatocytes. OCR at all time points is shown in Figure 4.12A.
Delta OCR (Figure 4.12B) was calculated by subtracting the OCR at the first
measured time point after CAA addition from the OCR baseline. CAA
treatment significantly increased delta OCR, indicating that OCR was
inhibited immediately after CAA addition. Importantly, pre-exposure cell to
Alda-1 significantly attenuated this effect.
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Scheme 4.1: Chronic animal model of VC and HFD
Mice were randomly divided into 6 groups and exposed to either VC (1ppm) or
room air (control) in our inhalation facility as described above. Alda-1 treatment
started 3 weeks prior to sacrificing.
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Figure 4.2. ALDH2 expression and enzymatic activity.
A: ALDH2 expression levels were measured in mouse liver mitochondria via
Western blot analysis, as well as densitometric analysis of ALDH2. VDAC
serves as a loading control for mitochondrial protein. B: ALDH2 activity was
determined as described in Chapter II. Results are reported as means ±
standard error mean (SEM; n=4-6). a, p<0.05 compared to LFD control, b,
p<0.05 compared to absence of VC.
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Figure 4.3. Metabolic phenotype of 12-week mice
A: Body weights of mice for all groups were monitored once per week over
the course of the 12-week exposure period B: Food consumption was
measured twice per week for the 12 weeks exposure period. C: Blood
glucose level at different time point was measured as describe in Chapter II,
OCTT area under curve stand for glucose tolerance is performed. Results are
reported as means ± standard error mean (SEM; n=4-6). a, p<0.05 compared
to LFD control, c, p<0.05 compared to absence of Alda-1.
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Figure 4.4. ALDH2 decreased liver injury caused by HFD and VC
A: Representative photomicrographs of H&E (general morphology, 200x) are
shown at the 12-week time point. B: Plasma transaminase (ALT/AST) levels
were determined for all the experimental groups at the 12-week time point. C:
Pathological score including inflammation and necrosis of all groups was
evaluated as described in Chapter II. Results are reported as means ±
standard error mean (SEM; n=4-6). a, p<0.05 compared to LFD control, b,
p<0.05 compared to absence of VC, c, p<0.05 compared to absence of Alda1.
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Figure 4.5. ALDH2 reduced liver inflammation in HFD and VC
A: Representative photomicrographs of CAE (neutrophils, purple) of all
groups are shown at the 200x magnification. B: CAE-positive cells were
counted and graphed as positive cells per 100 hepatocytes. Results are
reported as means ± standard error mean (SEM; n=4-6). a, p<0.05 compared
to LFD control, b, p<0.05 compared to absence of VC, c, p<0.05 compared to
absence of Alda-1.
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Figure 4.6. ALDH2 reduced oxidative stress in HFD and VC
A: Representative photomicrographs of MDA (index of oxidative stress,
brown) of all groups are shown at the 200x magnification. B: MDA levels in
liver were measured by TBARS assay as described in the previous section.
Results are reported as means ± standard error mean (SEM; n=4-6). a,
p<0.05 compared to LFD control, b, p<0.05 compared to absence of VC, c,
p<0.05 compared to absence of Alda-1.
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Figure 4.7. ALDH2 decreased CYP2E1 expression in liver of HFD+VC
A: Representative Western blot results of CYP2E1 expression are shown for
12 weeks mice. B: Densitometric analysis of CYP2E1 expression is graphed.
Results are reported as means ± standard error mean (SEM; n=4-6). a,
p<0.05 compared to LFD control, b, p<0.05 compared to absence of VC, c,
p<0.05 compared to absence of Alda-1.
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Figure 4.8. The effect of ALDH2 in lipids level
A: Representative photomicrographs of ORO (neutral lipid, red) are shown at
200x magnification. B: TG, FFA and cholesterol level of all groups were
measured as described Chapter II. Results are reported as means ± standard
error mean (SEM; n= 4-6), a, p<0.05 compared to LFD control, b, p<0.05
compared to absence of VC, c, p<0.05 compared to absence of Alda-1.
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Figure 4.9. The effect of ALDH2 in hepatic glycogen deposition
A: Representative photomicrographs of PAS (glycogen, dark purple) staining
are shown at 200x magnification. B: Hepatic glycogen expression of all
groups were measured as described in previous section. Results are reported
as means ± standard error mean (SEM; n= 4-6), a, p<0.05 compared to LFD
control, b, p<0.05 compared to absence of VC, c , p<0.05 compared to absence of Alda-1.
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Figure 4.10. The effect of ALDH2 on autophagy regulation
A: Representative western blot results for autophagy associated indices
expression level in liver: Atg7, p62, LC3I/LC3II, PINK1 and PARKIN. B:
Densitometric analysis for western blot is calculated by the ratio of intensity of
autophagy related protein to GAPDH. Results are reported as means ±
standard error mean (SEM; n= 4-6). a, p<0.05 compared to LFD control, b,
p<0.05 compared to absence of VC, c, p<0.05 compared to absence of Alda1.
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Figure 4.11. The effect of ALDH2 on cytotoxicity in primary hepatocytes
A: Representative photomicrographs depicting nuclear fluorescence
(Hoechst; blue), mitochondrial membrane potential (TMRM; red), cell
membrane permeability (TOTO-3; green) and intracellular calcium flux (Fluo4; pink) were determined in primary hepatocytes from 12-week modeled mice
using Cellomics HCS analysis. B: Fluorescence values analysis of TMRM,
TOTO-3 and Fluo-4 were performed. C: Representative photomicrographs
depicting nuclear fluorescence (Hoechst; blue) and mitochondrial superoxide
(MitoSox; red) were determined. D: Fluorescence values analysis of MitoSox
for each group are performed. a, p<0.05 compared to absence of VC, b,
p<0.05 compared to absence of Alda-1, c, p<0.05 compared to absence of
CAA treatment.
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Figure 4.12. ALDH2 protects mitochondrial respiration from CAA
A: OCR at different time point is measured in primary hepatocytes exposed to
CAA by Seahorse XF96 analyze as described in Chapter II. B: Delta OCR is
calculated by the subtracting the OCR at the first measured time point after
CAA addition from basal OCR value. a, p<0.05 compared to absence of CAA,
b

, p<0.05 compared to absence of Alda-1.
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C. Discussion
VC is an important hazard that causes many diseases. VC contaminated
water or air are the major ways to enter the human body and increase the risk
of multiple health problems, especially liver function. High concentrations of
VC (>100 ppm) have been demonstrated to cause hepatotoxicity. However,
the effects of low concentrations (< 1 ppm) of VC in combination with other
risk factors are understudied. Another independent risk factor that promotes
liver injury is obesity due to consumption of diets rich in fat. The pandemic of
obesity is arguably the most prevalent underlying disorder that impact US
population. Ingestion of large amounts of fat causes health complications
such as NAFLD, which is closely associated with metabolic syndrome.
Previous work in our lab also showed that low-dose exposure of VC
exacerbated NAFLD in the interaction of HFD (34). This conclusion is a
concern for occupational exposure and residential populations living in close
proximity to VC-contaminated sites. VC directly impairs hepatic mitochondrial
electron transport chain independent of diet (45, 78). In this section, we
hypothesize that VC will also affect mitochondrial ALDH2, an enzyme that has
previously shown to be protective. The aim was to explore the role of ALDH2
in the combination of low-dose VC and HFD, as well as the impact of ALDH2
in regulating cellular function using an in vitro model. For the mouse model of
VC inhalation, we used a concentration below the OSHA standard (<1 ppm, 8
hour/day) for12 weeks in combination with HFD feeding. We first determined
ALDH2 function as well as expression levels in this model.
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1. ALDH2 is impaired by VC and HFD.
ALDH2 is an important mitochondrial enzyme involved in several cellular
processes, notably in detoxification of alcohol-derived aldehyde. Ethanol is
transformed to acetaldehyde which can further be converted to acetate by
ALDH2. ALDH2 dysfunction causes aldehyde aggregation and increases
ROS production (38). The active site of ALDH2 contains a thiol group which is
sensitive to oxidative modification, making ALDH2 prone to oxidative
inactivation (30). The results summarized here showed that VC enhanced the
inhibition of ALDH2 activity in the interaction of HFD (Figure 4.2). Decreased
ALDH2 activity can be result from covalent modifications of the pivotal amino
acid residues of ALDH2 such as cysteine (79). Cysteine containing thiol
groups are sensitive to redox modifications. Furthermore, cysteine residues
can also be oxidized by endogenic aldehydes such as MDA and 4-HNE (80).
MDA and 4-HNE are products derived from lipid peroxidation, which can be
enhanced by ingestion of fatty acids (34); thus, feeding mice with HFD could
oxidize cysteine residues, leading to ALDH2 inactivation. Indeed, MDA
staining and quantitative TBARS levels were elevated by HFD feeding (Figure
4.6), which supports the previous observation of decreased ALDH2 activity.
Moreover, CAA (VC metabolite) was found to impair ALDH2 function directly
as shown in the previous chapter. In addition, Moon et al have reported that
inhibition of ALDH2 activity is mediated by phosphorylation via JNK (79).
Activated JNK is translocated to the mitochondria and phosphorylates serine
residues on ALDH2, causing conformational changes and contributing to the
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inhibition of ALDH2 activity (81). Chloroethanol (CE), as a metabolite of VC,
has been shown to increase JNK phosphorylation (82). Therefore, the
enhancing effect of VC on HFD-induced inhibition of ALDH2 activity, might be
regulated, in part through activating JNK-mediated phosphorylation. However,
the full mechanism of ALDH2 activity regulation by VC and HFD is still
unclear.
One reason for a decrease in enzyme activity can be alterations in protein
expression (83). We therefore expected a decrease in ALDH2 protein levels
in mitochondria isolated from mice fed a HFD. However, HFD significantly
increased ALDH2 expression (Figure 4.2). It has been shown that condensed
mitochondria with increased cristae membrane caused by HFD, could be due
to the overexpression of protein including ALDH2 (84). It is suggested that
this is a compensated upregulation of protein expression in response to
inhibition of the enzymatic activity caused by increased aldehyde toxicity. It is
also known that ɛPKC translocation mediated by HFD-induced ROS
production in mitochondria is a direct activator of ALDH2 expression (78).
Upregulation of ALDH2 expression contributes to recovery of mitochondrial
functional, improves metabolism of drugs and xenobiotic in liver (85). As
shown by Western blot (Figure 4.2), a decreased ALDH2 activity by VC
inhalation was only seen in HFD mice, however, VC decreased protein
expression levels independent of diet. These data suggest that VC exposure
inhibits ALDH2 enzymatic activity rather than affecting protein levels in the
LFD mice, but enhances ALDH2 impairment in both two aspects during
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additional risk factor exposure (HFD). Based on these findings, we confirmed
that VC exacerbates ALDH2 impairment in the HFD mice. Hence, we next
activated ALDH2 by Alda-1 in the HFD group to investigate the role of ALDH2
in liver function in the combination of HFD and VC.
2. ALDH2 reduced liver injury caused by HFD and VC
Previous work by our lab has shown that low concentrations of VC
increase the risk of liver damage in the present of HFD (34). Consistently, we
showed VC promoted hepatic aminotransferase level including AST and ALT
in the mice with HFD. AST and ALT are the representative and sensitive
enzymes that can be elevated in response to liver injury in humans and
animals. Activation of ALDH2 significantly blunted the increase in
transaminase levels as well as pathological morphology (e.g. inflammation) in
livers of the HFD mice (Figure 4.4). Indeed, the increased neutrophil
infiltration in the HFD mice by VC inhalation was reversed by Adla-1
administration (Figure 4.5), indicating that hepatic inflammation and injury
was attenuated by ALDH2. Neutrophil recruitment can be induced by
chemokines such as lipopolysaccharide-induced CXC chemokine (LIX) which
serves as the mediator of neutrophil recruitment that can be induced by
oxidative stress (86). Decreased neutrophil accumulation by Alda-1 might
therefore be due to the inhibition of oxidative stress-induced inflammatory
chemokines. ALDH2 restores disruption of energy metabolism, reduces
inflammation, decreases oxidative stress and protects liver function.
Furthermore, increased hepatic MDA in the mice of HFD+VC was decreased
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by Alda-1 treatment (Figure 4.6), supporting that ALDH2 reduced liver injury
is via suppressed lipid mediated oxidative stress. Additionally, CYP2E1
expression was increased in the HFD groups and this was reversed by Alda-1
intervention (Figure 4.7). CYP2E1 is known to be a contributor to oxidative
stress (87), decreased CYP2E1 level by Alda-1 demonstrated that ALDH2
activation protected liver from oxidative stress. These data demonstrated that
ALDH2 is critical in protecting the liver against damage due to environmental
toxicant exposure and dietary fat.
HFD and VC are risk factors that have been shown in our previous studies
to cause disruption of hepatic metabolism (34). Energy metabolism includes
lipid and carbohydrate homeostasis. Abnormal fat or glycogen storage in liver
can cause cell damage. An overload of lipid accumulation is associated with
cellular oxidative stress caused by aldehyde production, which result from
lipid peroxidation. Metabolic phenotyping (Figure 4.3) showed that HFD
increased body weight and blood glycose level of the mice, however VC
addition did not enhance these effects. ALDH2 activation caused an opposite
trend in the HFD mice. Consistent with the observations in body weight, HFD
increased macrovesicular steatosis as depicted in ORO staining and
quantitative hepatic TG levels, as well as microvesicular lipids (FFA and
cholesterol) (Figure 4.7). TG levels were enhanced by VC exposure whereas
FFA and cholesterol were not changed significantly. It suggested that VC has
a stronger effect on regulating hepatic TG level rather than FFA and
cholesterol level in the HFD group. We hypothesized that VC addition may
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increase lipogenetic gene expression involved in TG synthesis such as
peroxisome proliferated-activated receptor γ (PPARγ) and sterol regulatory
element-binding protein-1c (SREBP-1c) in the HFD mice (88). All these
markers were reduced by ALDH2 intervene except cholesterol. TG is thought
to be the main component of fats, decreased lipids accumulation or steatosis
by Alda-1 is predominantly attributed to ALDH2 mediated TG downregulation.
Even though cholesterol was elevated after Alda-1 treatment, we believed the
total effect of these forms of lipids in the HFD+VC was suppressed by
ALDH2.
However, the mechanisms of ALDH2 involvement in lipid regulation
remains unclear. It has been shown in mice that after Alda-1 treatment the
most upregulated proteins were related to β-oxidation of fatty acid in
mitochondria such as enoyl-Coenzyme A hydratase (ECHS1) and acetylCoenzyme A acyltransferase 2 (ACAA2) (81). These proteins assist with fatty
acid degradation and ameliorate TG and FFA content in the liver. On the
other hand, ALDH2 activity may also affect hepatic lipogenesis. You et al.,
found that acetaldehyde increased SREBP1 known as a mediator in lipid
synthesis, inhibition of ALDH2 enhanced SREBP1 expression thereby leading
to fatty liver (89). These studies may explain how ALDH2 regulates lipids
storage in liver. Together with mice phenotype, these data affirmed that
ALDH2 activation attenuated hepatic steatosis caused by HFD and VC.
Glucose homeostasis is also an important component of energy
metabolism. HFD has been demonstrated to elevate blood glucose in our
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study (Figure 4.3C). This was also previously demonstrated by increased
insulin resistance as measured by ITT performed (34). Insulin resistance not
only controls blood glucose but also is related to dyslipidemia (e.g. increased
TG level) (90). Moreover, lipid peroxidation derived aldehydes could induce
insulin resistance and result in metabolic syndrome (91). Alda-1 treatment
was shown to decrease blood glucose in the HFD group, indicating a
reversed effect of ALDH2 on glucose intolerance (Figure 4.3C). The role of
ALDH2 in ameliorating insulin insensitivity has been demonstrated to act via
regulating insulin signaling factors such as insulin receptor substrate (IRS)
(50). We also found that decreased storage of glycogen in liver by HFD can
be blunted by ALDH2 (Figure 4.9). HFD-induced FFA production inhibited
glycogen synthesis (92), leading to energy depletion and lipids synthesis
(causing steatosis) (34). ALDH2 has been reported for its role in regulating
cellular glycogen synthesis related transcriptional factors including AKT, as
well as its downstream target GSK3. It is known that inactivation and
phosphorylation of GSK3 by AKT induction increases glycogen synthesis
(93). Zhang and colleagues observed that Alda-1 increased activation of
AKT/GSK3 signalling pathway leads to cardio-protection in an experimental
diabetes model (94), suggesting that increased ALDH2 activity ablated cell
damage via participating in AKT/GSK3 pathway and regulating glucose
homeostasis. In the HFD+VC group, however, there was no significant
difference in glycogen level after Alda-1 treatment. We hypothesize that VC
impacts factors involving in the ALDH2 mediated glucose or glycogen
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regulation. Taken together, these data suggest that ALDH2 plays a role in
protecting impaired energy metabolism from HFD and VC.
3. The mechanisms involved in the role of ALDH2 in liver injury of
HFD and VC
We demonstrated that ALDH2 played a role in protecting the liver in the
interaction of HFD and VC. However, the mechanisms of ALDH2 activation in
hepato-protection remains elusive. We have shown that VC and HFD
associated liver injury could be via increased inflammation, oxidative stress
and metabolic homeostasis disruption. During the response to stress, cells
initiate rapid changes to guarantee survival and to protect themselves against
harmful conditions. Autophagy is one of the key pathways that mediate
stress-induced adaption and damage control, allowing cells to eliminate
damaged components such as organelles, proteins and portions of cytoplasm
(71). LC3II is associated with the autophagic membrane and acts as an
indicator of autophagy. However, here Alda-1 did not change LC3II
expression (Figure 4.10). It is also known that p62 can be degraded by the
autophagy-lysosome pathway, and an increase in p62 protein levels may
result from impaired autophagy (60). Here, we found that Alda-1 significantly
decreased p62 protein expression in the HFD and HFD+VC groups (Figure
4.10), possibly suggesting increased autophagy to protect from liver injury
caused by HFD and VC. From our previous work, we know that VC promotes
mitochondrial dysfunction in mice (34). Cells keep quality control by removing
damaged mitochondria via mitophagy. This process is mediated by the
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PINK1/PARKIN pathway. Here, Alda-1 was shown in the HFD+VC mice to
decrease PINK1 and PARKIN expression, suggesting an inhibition of
mitophagy (Figure 4.10). Ji et al., have also shown that ALDH2 activation had
a protective effect on cells via suppressing PINK1/PARKIN mediated
mitophagy (47). ROS-induced mitochondrial damage is an important
upstream activator of mitophagy, and the PINK1/PARKIN pathway may be
activated in response to oxidative stress induced cell damage (47). ALDH2
activation by Alda-1 reduced oxidative stress caused by HFD and VC,
suggesting to play a role in mitochondrial protection. It seems paradoxical that
ALDH2 activation protects mitochondria by inhibition of mitophagy. We
hypothesize that under severe pathophysiologic conditions, such as oxidative
stress, excessive mitophagy was triggered and caused mitochondrial fission
and loss, which was detrimental to mitochondrial quality control (95).
Activation of ALDH2 attenuated oxidative stress and suppressed
PINK1/PARKIN-mediated mitophagy, resulting reduced mitochondrial injury.
Thus, we proposed that ALDH2 has a dual regulatory role in autophagy to
protect liver from HFD and VC.
Further, we studied ALDH2 function at the cellular level for cytotoxicity
related indices, including mitochondrial membrane potential (TMRM), cell
membrane permeability (TOTO-3), intracellular calcium ion (Fluo-4) and
mitochondrial superoxide (mitoSox). As shown in the data above, ALDH2
ameliorated liver injury by reversing disruption of energy metabolism and
oxidative stress, both of which are linked to mitochondria. Mitochondrial
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membrane potential is a representative marker of mitochondrial function,
serving as an intermediate involving in ATP synthase (74). Oxidative stress is
an inducer of mitochondrial depolarization or Mitochondrial membrane
potential loss, leading to mitochondrial dysfunction and deleterious effects
(96). ALDH2 activation was shown to inhibit oxidative stress caused by HFD.
However, there was no significant difference of TMRM fluorescent intensity
found in Alda-1 groups compared to their controls (Figure 4.11). Intracellular
calcium is known as one of the key events that causes mitochondrial injury
via ROS generation, such as superoxide (97, 98). These markers were
unchanged by ALDH2 activation as depicted by the cellomics assay. This
suggests that the protective role of ALDH2 in hepatocytes of chronic HFD and
VC model is not mainly controlled by regulation of calcium or superoxide
related mitochondrial membrane potential. We additionally determined that
Alda-1 treatment didn’t alter TOTO-3 fluorescent intensity, which implied an
unchanged cell membrane permeability during chronic HFD feeding.
Previously, we have shown that ALDH2 increased mitochondrial membrane
potential and decreased membrane permeability in the acute 4-HNE
exposure (45). This paradoxical role of ALDH2 in these cytotoxicity indices,
might be due to a cellular adaption in response to prolonged conditions of
stress. When the cells are suffering from long-term harmful factors,
mitochondrial membrane potential and cellular membrane permeability may
be more compromised to the cellular stress and therefore not sensitive to
ALDH2 mediated regulation.

91

Via Seahorse analysis, OCR was measured in primary mouse
hepatocytes immediately after adding CAA. CAA decreased OCR and this
effect was blunted by Alda-1 pre-incubation. However, this effect only
occurred at the very beginning and disappeared as time progressed (Figure
4.12). We propose that ALDH2 activation protects mitochondrial respiration
from short-term damage. CAA is a strong mitochondrial toxicant and the
extent of the damage caused by CAA exceeds the protective properties of
ALDH2 activation. ALDH2 catalyzes the conversion of CAA in the presence of
NAD+ and forming NADH. In our Seahorse experiment, we did not supply
extra NAD+, while NAD+ was consumed as time progressed. Thus, it might be
possible that the effect of ALDH2 in degrading CAA was decreased due to
insufficient coenzyme. Additionally, it is proposed that Alda-1 has an inhibitory
effect on ALDH2 when aldehyde levels are at a low concentration. Binding of
Alda-1 to ALDH2 induces a change in the sequence of binding of substrate to
enzyme. Alda-1 promotes a decrease of the pKa of the catalytic cysteine,
which may facilitate the nucleophilic attack to the aldehyde prior to NAD +.
Alternatively, NAD+ could bind to ALDH2 as the first substrate and form the
non-productive complex (Alda-1-ALDH2-NAD+). When aldehyde levels are
low, the non-productive complex is predominantly formed and this complex
can decrease catalytic reaction rate (99). In our study, CAA concentration
was high at beginning, binding of Alda-1 to ALDH2 accelerated CAA
catalysis. As the reaction continued, substrate of CAA was lower, the
substrate binding sequence might be changed and resulted in the formation
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of the non-productive complex, which inhibited ALDH2 function, leading to a
decreased mitochondrial protection. These data might also explain the
discrepant role of ALDH2 in mitochondrial dysfunction caused by different
time point-depended deleterious factors exposure.
Mitochondrial membrane potential is known to not only play a role in
energy supply but also participate in the process of elimination of damaged
mitochondria (74). It has been demonstrated that mitophagy mediated by
PINK1/PARKIN signal is triggered by depolarization of the Mitochondrial
membrane potential (100). Interestingly, the mitochondrial membrane
potential in ALDH2 was not consistent with PINK1/PARKIN expression.
However, mitochondrial membrane potential is not the only factor in
regulation of PINK1/PARKIN-mediated mitophagy. There are other signalling
factors participating in this process. It has been found that Nrf2 is a novel
transcriptional upregulator of Pink1 genes via the activation of an antioxidant
responsive elements (ARE) sequence in the promotor of PINK1. Nrf2 is
normally in the cytosol and degraded by KEAP1. While under oxidative stress
conditions, oxidants and electrophiles oxidize cysteine residues in KEAP1
and increase Nrf2 release, leading to PINK1 increase (101). Additionally,
ATF4, known as the marker of ER stress involved in liver damage (102), is
demonstrated to upregulate PARKIN by binding to a specific CREB/ATF site
within PARKIN promoter (103). As discussed before, augmented mitophagy
under severe condition could be deleterious to mitochondria. We hypothesize
that excessive PINK1/PARKIN-mediated mitophagy might be triggered by
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increased oxidative and ER stress. ALDH2 decreased oxidative stress may
attenuated Nrf2 mediated PINK1 promotion. It has been shown that ATF4
upregulation is associated with ALDH2 impairment (104). We suggest that
ALDH2 inhibited PINK1/PARKIN signal pathway might be due to the
suppressed oxidative and ER stress. These data also suggest complex and
mixed mechanisms of ALDH2 in protecting mitochondria. In the early state of
liver injury, ALDH2 activation may have increased PINK1/PARKIN signalling
via preserving mitochondrial membrane potential (45, 105) and plays a role in
mitochondrial protection, partly to attenuate cell damage. As the time went on
or under more severe conditions, more excessive mitophagy may have
occurred and impaired mitochondrial homeostasis. The severe degree of
mitochondrial membrane potential depolarization might not be rescued by
ALDH2 regulation, thus, ALDH2 may shunt to regulate other factors (e.g.
Nrf2, ATF4) and suppress PINK1/PARKIN-mediated mitophagy, protecting
mitochondrial function.

D. Conclusion
In this aim, we employed a model of chronic low-dose VC exposure in
mice fed with a HFD and studied the role of ALDH2 in this combination as
well as the related mechanisms in vivo and in vitro. Both ALDH2 enzymatic
activity and expression level were impaired in the interaction of HFD and VC.
This impairment contributes to liver injury via increased aldehyde levels and
related oxidative stress. Activation of ALDH2 accelerated aldehyde clearance
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and provided a protective effect. Additionally, ALDH2 plays a role in reversing
metabolic disorder including lipids/carbohydrates and inhibiting inflammation
caused by HFD and VC. This protection by ALDH2 activation can be
mediated by some signalling factors. ALDH2 decreased p62 expression,
indicating increased autophagy resulting in the removal of damaged proteins
or components in hepatocytes. Further, ALDH2 was demonstrated to inhibit
PINK1/PARKIN-induced mitophagy, to decrease excessive mitophagy and to
act a regulator of mitochondrial quality control. Impairment of the
mitochondrial respiratory chain by CAA was reflected in a decrease in OCR of
hepatocytes. This effect was attenuated by ALDH2 activation, suggesting that
ALDH2 activation protects mitochondrial respiration from the toxic effects of
CAA. Overall in this aim, we demonstrated that ALDH2 alleviated liver
damage in the interaction of chronic VC exposure and HFD, via decreasing
oxidative stress and inflammation, reversing metabolic dysfunction, regulating
autophagy and protecting mitochondrial function (Scheme 4.2).
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Scheme 4.2: regulation of ALDH2 in liver injury caused by HFD and VC
ALDH2 dysfunction is involved in the liver injury caused by HFD and VC,
which is due to an increased aldehydes attack. Activation of ALDH2 plays a
role in protecting liver function against HFD and VC by decreasing oxidative
stress, inflammation, protecting mitochondrial function and regulating
autophagy.
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CHAPTER V

SUMMARY AND CONCLUSION

A. Aims in this study
VC and obesity are the independent risk factors that are known to induce liver
injury. Our group has previously observed that low-dose of VC exposure
exacerbated liver damage in HFD-fed mice and started to gain insight into the
associated mechanisms (34). ALDH2 is known to play a protective role in the
many diseases. However, whether it ameliorates liver injury caused by HFD and
VC has not been studied. The overall goals in this dissertation were to
investigate the role of ALDH2 in the interaction of VC and HFD. For that goal, we
set two aims. The first aim was to determine the effect of ALDH2 in an acute
setting of VC metabolite exposure. Part of that aim was also to study the catalytic
activity of ALDH2 protein under exposure to CAA, as described in Chapter III.
The second aim described in Chapter IV was to characterize the role of ALDH2
in liver injury caused by chronic low-dose VC exposure and HFD. Taken
together, these studies provide the evidences that ALDH2 plays a role in
protecting liver function by regulating complex mechanisms of liver injury.
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B. Major findings in this dissertation
1. Protection of ALDH2 enzymatic activity reduced liver injury
against acute CE exposure
Since CE is a major metabolite of VC, the role of ALDH2 on liver function
after CE exposure serves as an indicator to evaluate its impact in mice
exposed to a moderately high, acute dose of VC. Mice therefore received CE
at concentrations equal to high-level VC inhalation that caused liver damage.
In Chapter III, we first determined the effect of ALDH2 in the disease
phenotype. CE was shown to disrupt hepatic carbohydrate and lipid
metabolism as presented by histologic staining and quantitative
measurements. ALDH2 activation reversed lipid (e.g. TG) accumulation in the
CE group while it did not increase glycogen stores. When looking at the
expression of metabolism related genes, ALDH2 increased cpt1 expression
supporting a promotion of FFA β-oxidation in the mitochondria. These data
may explain the fact that ALDH2 decreased lipid storage. Previous work in
our lab showed that CE increased 4-HNE adduct formation after LPS
administration (30). It has also been shown previously that 4-HNE adduct
formation can be inhibited by ALDH2 (45). Therefore, oxidative stress was
also assessed in this aim. As expected, ALDH2 decreased 4-HNE adduct
formation induced by CE, indicating that lipid peroxide levels were attenuated
by ALDH2 activation. Overall, we demonstrated that ALDH2 prevented liver
injury caused by CE exposure via reducing hepatic steatosis and oxidative
stress.
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The second aim in Chapter III was to explore a direct reaction between
ALDH2 and CAA. ALDH2 catalyzes aldehydes into nontoxic acids with NAD+
as a cofactor. We showed that ALDH2 degraded CAA, which was initiated
immediately by addition of NAD+. ALDH2 pre-incubation with CAA showed
lower catalytic activity after adding NAD+ . This result suggests that CAA is not
only the substrate but also an inhibitor of ALDH2. Activation of ALDH2 prior to
CAA exposure rescued the inhibition of the enzymatic activity caused by
CAA. These data demonstrated that ALDH2 activation by Alda-1 pretreatment prevented enzyme function from CAA. The preserved ALDH2
catalytic activity accelerated elimination of toxic aldehydes such as 4-HNE
and CAA, removed aldehyde-related oxidative stress, and therefore
protecting the liver from the detrimental effects of VC metabolite exposure.
2. ALDH2 dysfunction is involved in the liver injury caused by HFD
and VC
As described in Chapter III, we found that ALDH2 activity was impaired by
CAA. It is reasonable to speculate that ALDH2 function will also be inhibited
by VC inhalation in HFD-fed mice. First, in Chapter IV, we measured ALDH2
expression as well as enzymatic activity in chronic low-level VC exposure in
combination with HFD. HFD decreased ALDH2 activity but increased protein
expression, likely as a compensatory reaction. VC however, decreased both.
These data supported our hypothesis that ALDH2 dysfunction is critically
involved in the interaction of VC and HFD. In the in vitro experiment as
described in Chapter III, we demonstrated ALDH2 activity played a protective
99

role in the liver during exposure to VC metabolites. That provided a strong
rationale to assume that ALDH2 activation attenuated liver injury caused by
HFD and VC.
3. ALDH2 activation reduced liver injury of VC and HFD through
protecting mitochondrial function
Previously we have found that VC exacerbated liver damage in the HFD
mice involving multiple mechanisms including metabolic dysfunction,
oxidative stress, and to a lesser extent, inflammation (34). Thus, these
hallmarks were measured as described in Chapter IV for evaluating the role
of ALDH2 in the combination of VC and HFD. Indices of liver injury,
transaminases activity (AST, ALT) were decreased by ALDH2 activation in
the VC and HFD group. The effect of VC inhalation and dietary fat on the
hepatic general morphology was also improved by ALDH2 activity, particularly
neutrophil infiltration was decreased. Increased lipid accumulation (e.g. TG,
FFA) mediated by HFD and VC was alleviated by ALDH2, while the reversed
effect of ALDH2 on depleted glycogen was only observed in HFD group.
Oxidative stress-mediated liver damage has been studied previously, as
aldehydes derived from lipid peroxidation are known substrates of ALDH2
(58). Steatosis caused by HFD+VC was associated with elevated toxic
aldehyde production such as MDA. ALDH2 catalyzed MDA degradation and
ameliorated oxidative stress in liver of HFD and VC. Furthermore, we
measured the expression of CYP2E1 in response to ALDH2 activation.
CYP2E1 is not only known as the critical enzyme for drug metabolism but
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also serves as an inducer of ROS. ALDH2 decreased CYP2E1 levels and
partly ameliorated oxidative stress.
Cells often evoke an adaptive process in response to such stressmediated injury. Autophagy is one of the key pathways allowing cells to
eliminate damaged components for quality control, homeostasis of
organelles, proteins and portions of cytoplasm. Atg7, LC3 and p62 are the
factors typically regulating autophagy (71, 72). ALDH2 did not alter Atg7 and
LC3 expression in the HFD and VC but decreased p62 expression, which
suggested an increase in autophagy by ALDH2. Selective autophagy termed
mitophagy is initiated by PINK1/PARKIN signal pathway and these markers in
the HFD and VC were suppressed by ALDH2. Previous work in our group has
demonstrated mitochondrial dysfunction was induced by aldehydes such as
4-HNE in the in vitro experiments (45). We hypothesized that ALDH2
decreases mitophagy due to its function in reducing oxidative stress in
mitochondria. Moreover, decreased OCRs in hepatocytes after CAA addition
was blunted by pre-treatment of Alda-1, indicating that impaired mitochondrial
respiration was prevented by ALDH2 activation. However, we found that this
protection did not persist. Moreover, ALDH2 showed no effect on cytotoxicity
indices (e.g. mitochondrial membrane potential) in the HFD fed mice. It is
possible for ALDH2 to play a role in protecting liver via different patterns
according to different time point exposure of risk factors.
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Summarized table 1: The effect of ALDH2 in indices change in VC
metabolites exposure

Summarized table 2: The effect of ALDH2 in indices change VC and
HFD exposure
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C. Significance
In the United States, NAFLD is becoming the most common cause of liver
disease that leads to a non-negligible health problem. Obesity and
environmental toxicants are two independent risk factors causing liver injury.
VC, as the representative toxicant has been demonstrated to exacerbate liver
damage at a low-dose level in the presence of a HFD (34). This model
allowed us a better understanding of the underlying mechanisms in the
interaction of VC and obesity, which provided the rationale for determining a
target to protect the liver from injury. ALDH2 is a mitochondrial enzyme
known for its role in ethanol metabolism and its participation in protecting
organs from not only alcohol but also other stress (78). The effect of ALDH2
in the interaction of VC and HFD induced liver injury remains elusive. In this
project we found that ALDH2 impairment is, at least in part, involved in the
deleterious effects of VC and HFD. Indeed, ALDH2 activation by Alda-1
protected the liver from the detrimental effects of not only acute VC
metabolite exposure but also of chronic exposure to HFD and VC.
Our model of low-dose VC inhalation and HFD feeding mimics the
situation of subjects living/working near manufacturing and/or superfund sites
who are also likely to ingest a Western style diet, rich in fat and
carbohydrates. Based on our findings, we raised several concerns for this
kind of population: 1) subjects with ALDH2 dysfunction or deficiency
(ALDH2*2 allele) might be more susceptible to liver damage caused by VC
exposure and dietary fat. Therefore, we suggest that screening for these
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ALDH2 activity defects might be beneficial for these subjects. 2) For those
subjects who have ALDH2 impairment, ALDH2 activation by Alda-1 will serve
as a potential therapeutic target. These proposed concerns are based on the
experimental animal data. The effect of ALDH2 in humans needs further
investigation.

D. Strength
Liver disease caused by high-level VC exposure has been studied
extensively, however, the effect of low-level VC exposure on liver function is
largely understudied. Our group focuses on the impact of chronic
administration of sub-OSHA concentrations of VC exposure (<1 ppm) on liver.
Indeed, in our previous work, we observed the importance of VC exposure on
hepatic metabolism, oxidative stress activation, and mitochondrial
dysfunction. This effect was exacerbated when combined with a HFD. These
findings suggested that even low-dose VC exposure may not be safe for
people in combination with other factors, such as diets rich in fat. Moreover,
there are no potential targets for therapy known to halt or reverse the disease.
Therefore, seeking such a target was a major focus of this study.
In this work, we focused on the effect of ALDH2 in liver injury. Although
ALDH2 has been shown to reduce liver injury caused by alcohol, the role of
ALDH2 in our animal model remains unclear. We employed an animal model
to closely mimic human exposure of VC and co-exposure of HFD. The major
goal was to investigate whether activation of ALDH2 by Alda-1 changed the
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disease phenotype. ALDH2 activation was found to improve the dysregulated
energy metabolism and to decrease oxidative stress in this model. We also
used the state-of-the-art techniques such as Cellomics Assay Scan VTI HCS
reader and XF96 Extracellular Flux Analyzer to gain insight into the role of
ALDH2 in mitochondrial function. Indeed, ALDH2 activation protected
mitochondrial respiration from the toxic effects of CAA.
This dissertation revealed that ALDH2 plays a role in the mechanisms
involved in liver injury caused by VC and HFD, and that its activation may
protect the liver in this model. Other related organochlorine contaminants
such as TCE and PCE, that have also been demonstrated to cause liver
injury, could also be following a similar pathway (e.g. oxidative stress) (70).
This work provides rational evidence that ALDH2 is a potential target in
preventing liver injury from chlorinated solvent mixtures.

E. Weakness
In this dissertation, the role of ALDH2 in liver protection against VC and
HFD was shown in an animal model. Animal models may not completely
mimic human liver disease progression. Therefore, the effect of ALDH2 in
regulating liver function may not be applicable to a human population.
Moreover, multiple factors participate in the liver damage, it is therefore
difficult to identify an exact pathway. We here showed the role of ALDH2 in
altering disease phenotype in mice, however, we did not perform a direct
regulation of ALDH2 at molecular level in liver protection in the animal model.
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Additionally, only male mice were used in this study. It is important to note the
effects observed may vary with sex. Indeed, recent data by Wahlang et al.,
(unpublished observation) showed that female mice are less susceptible to
liver injury caused by VC and HFD.

F. Future direction
1. Investigate how CAA modulates ALDH2 activity
ALDH2 contains a catalytic domain and a NAD+ binding domain. Cys302
is known as the main aldehyde binding site in the catalytic domain of ALDH2
for aldehydes clearance (38). It has been also proposed that Cys302 is the
target for ALDH2 inactivation by 4-HNE. Additionally, it has been observed
that the Lys residue in the NAD+ binding site of ALDH2 is susceptible to be
targeted by toxic aldehydes such as acrolein (58). In our work, we have
shown that chronic VC exposure decreased ALDH2 activity in an animal
model, and that CAA pre-incubation binds to the active site and therefore
inhibiting NADH formation. These findings suggested that VC or its
metabolites react with residues within the ALDH2 enzyme and therefore
decrease its catalytic activity. However, how these active sites were regulated
remains subject to further studies. Although ALDH2 shows a high affinity of
toxic aldehydes, this enzyme also was sensitive to inactivation reversibly or
irreversibly by these toxicants. It would be beneficial to have a more in-depth–
understanding of the interaction between enzyme and aldehydes.
2. Investigate whether Alda-1 protects liver injury from VC and HFD
in defect ALDH2 mice
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The most prevalent ALDH2 variant is ALDH2 2*2 allele, which is found in
the 35-45% Asian population (38). The ALDH2 2*2 has a lower catalytic
activity than the wild-type allele. For those subjects with an ALDH2 mutation,
it would be beneficial to know whether Alda-1 still protects liver function.
ALDH2 2*2 knock-in mice may serve as an ideal experimental model for the
research of human diseases associated with ALDH2 deficiency. In our study,
we demonstrated that activation of ALDH2 by Alda-1 reduced liver injury
caused by VC and HFD in the wild-type mice. Moreover, Alda-1 is shown to
activate both human and mouse ALDH2 2*2 enzyme with a similar potency
profile and activation kinetics (38). It is likely that Alda-1 treatment also
protects ALDH2 deficient livers against environmental toxicants and dietary
fat.
3. Investigate whether ALDH2 activation prevents liver against
chronic VC and HFD
In Chapter IV, we demonstrated that ALDH2 intervention reduced liver
injury caused by chronic exposure of VC and HFD. In mice exposed to longterm noxious compounds, ALDH2 impairment may occur in an early stage of
liver damage (ALDH2 dysfunction was measured at the 6 week time-point of
the animal model; data not shown). Aldehydes including 4-HNE, MDA and
CAA caused ALDH2 inactivation may not be completely reversed by Alda-1
treatment. As the toxicant exposure continues, the effect of Alda-1 on ALDH2
activation may not be strong enough to maintain the protective effect in liver
damage. In Chapter III, we observed that pre-treatment of Alda-1 protected
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livers from acute CE exposure. It is promising that pre-treatment of Alda-1
prevent liver damage from chronic VC and HFD.

G. Summary and conclusion
Taken together, this dissertation described ALDH2, an enzyme as a
potential therapeutic target in the novel interaction between of chronic VC
exposure and dietary fat. The experiments described in Chapter III revealed
that ALDH2 played a role in the preventing liver injury caused by acute CE
exposure. This effect was due to the decreased oxidative stress and reversed
metabolic dysfunction. Inhibition of ALDH2 activity by CAA was prevented by
Alda-1 pre-incubation. These findings showed that ALDH2 function in this
phenotype might be mediated via a preservation of enzymatic activity by
Alda-1. Chapter IV demonstrated that ALDH2 dysfunction was a part of the
mechanisms mediating liver damage in the interaction of chronic VC
exposure and HFD. Indeed, activation of ALDH2 reduced indices of liver
injury in this combination. Additionally, metabolic stress, oxidative damage
and impaired autophagy were observed to be affected by ALDH2. This could
result from an intact mitochondrial function. Activation of ALDH2 by Alda-1
increased toxic substrate elimination, which attenuated oxidative stress and
protected mitochondrial respiration. Therefore, energy metabolism and
autophagy (mitophagy) were also improved. Overall, this project
demonstrated the role of ALDH2 in liver protection using an experimental
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animal model. In our future studies, we will further explore the mechanisms in
this model.
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ABBREVIATIONS

4-HNE

4-Hydroxynoneal

ACLY

ATP citrate lyase

AFLD

Alcoholic fatty liver diseases

ALDH 2

Aldehyde dehydrogenases 2

ALT

Alanine aminotransferase

ANOVA

Analysis variation

ASL

Angiosarcoma of the liver

AST

Aspartate aminotransferase

ATF4

Activating transcription factor 4

ATSDR

Agency for Toxic Substances and Disease Registry

BMI

Body mass index

CAA

Chloroacetaldehyde

CAE

Chloroacetate esterase

CE

Chloroethanol

CPT1

Carnitine palmitoyltransferase 1
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CREB

CAMP responsive element binding protein 1

CYP

Cytochrome P450

DCE

Dichloroethylene

EPA

Environment Protection Agency

ER

Endoplasmic reticulum

FAS

Fatty acid synthase

FFA

Free fatty acid

GCK

Glucokinase

GLUT4

Glucose transporter 4

GSK3b

Glycogen synthase kinase 3b

H&E

Hematoxylin and eosin

HCC

Hepatocellular carcinoma

HFD

High-fat diet

IHC

Immunohistochemistry

KEAP1

Kelch-like ECH-associated protein 1

LC3

Microtubule-associated protein light chain 3

LFD

Low-fat control

LIX

Lipopolysaccharide-induced CXC chemokine
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MDA

Malondialdehyde

NAFLD

Non-alcoholic fatty liver disease

NASH

Non-alcoholic steatohepatitis

NEFA

Non-essential fatty acid

Nrf2

Nuclear factor-like 2

OCRs

Oxygen consumption rates

OGTT

Glucose tolerance test

ORO

Oil Red-O

OSHA

Occupational Safety and Health Association

p62

Sequestosome 1

PAI-1

Plasminogen activator inhibitor 1

PAS

Periodic Acid-Schiff

PCE

Tetrachloroethene

PCK

Phosphoenolpyruvate carboxykinase

PINK1

PTEN-induced kinase 1

PPARγ

Peroxisome proliferated-activated receptor γ

Ppm

Parts per million

PVC

Polyvinyl chloride

ROS

Reactive oxygen species
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SREBP-1c

Sterol regulatory element-binding protein-1c

TASH

Toxicant-associated steatohepatitis

TBARS

Thiobarbituric acid reactive substances

TCE

Trichloroethene

TG

Triglyceride

TNF-α

Tumor necrosis factor-α

VC

Vinyl chloride

VDAC

Voltage-dependent anion channel
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